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The treatment of symptoms associated with menopause and the prevention of 
chronic disorders among post-menopausal women have been intensely debated both in 
the medical community and in the public during the last five or six decades. 
Before the “hormone therapy (HT) for prevention” era of the 1990s, an 
international debate on menopause and hormone therapy (at that time called hormone 
replacement therapy – HRT) as an example of medicalisation had taken place. From 1990 
onwards, HT was generally advocated as a reliable prevention for chronic diseases among 
postmenopausal women, especially osteoporosis, coronary heart disease, urinary 
incontinence and also cognitive loss and dementia. During a short time span around the 
turn of the millennium, the evidence base for hormone therapy (HT – estrogen and 
estrogen/gestagen therapy) during and after the menopause changed profoundly. Results 
from randomized controlled trials and new results from observational studies showed that 
HT did not prevent cardiovascular disease and led to increased risk for breast cancer. The 
findings led to a complete reversal of the treatment recommendations. According to the 
Norwegian recommendations, the indication for HT is bothersome hot flushes with a 
negative influence on quality of life, and the treatment should be revised annually.
The general practitioners (GPs) in Norway prescribe about half of the HT
medicaments and they are important discussion partners for women in this age. The first 
part of the thesis, the GP study, deals with the attitudes and knowledge among Norwegian 
GPs regarding HT after the new evidence was published and the changing of the 
Norwegian recommendations. What did the GPs think about their role in prescription, and 
how did they assess the risks and side effects of the treatment? Did the GPs give different 
advice to the women, and if so, which factors were associated with these differences? We 
also wanted to investigate the use of HT among female GPs themselves.
A random sample of 400 GPs were in May 2004 invited to participate, and 289 (72 %) 
returned a completed questionnaire. Three of the questions were formulated as clinical 
examples where doctors were requested to give an opinion about whether they would 
advise using HT or not, and they could also give their own comments.
The results are published in Paper I and II in the dissertation. In 2004, most Norwegian 
GPs were familiar with the current evidence base regarding the effects and side effects of 
HT, and that they followed the recommendations regarding indications and contra-
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indications. A large majority of the respondents agreed to the statements that hormone 
therapy increases the risk of breast cancer, that it does not prevent myocardial infarction 
and that the most important reason to prescribe hormone therapy is bothersome hot
flushes. Female GPs seemed better updated on some aspects of the treatment than male 
doctors, while at the same time 14 out of 17 (82 %) peri- and postmenopausal female GPs 
were using or had used such treatment. A majority of the GP’s agreed to the statement 
that HT improves sex life, and almost half of the GP’s believed that HT counteracts aging 
of the skin. The doctors were asked to agree or disagree to a statement that HT implies an 
undesirable medicalisation of a natural life phase in women.  One third of the GPs agreed, 
while some more (44 %) disagreed and 24 % were neutral to the statement. None of the 
background factors (e.g. age or gender) predicted the standing on this question.
When doctors were requested to give an opinion on clinical examples, they were 
notably divided in their view on therapy or not. The attitude to HT (elicited through the
medicalisation question) was the most important predictor for the advice given, and 
perception of indications, contraindications and effects of HT played a lesser role in the 
judgment. Those who did not agree to the medicalisation statement were most in favor of 
treatment.
In the second part of the dissertation, the HWC Study, the aim was to describe the 
natural course of menopause and the use of HT in a representative female cohort in 
Norway. A particular aim was to analyze symptom prevalence over time during the 
natural menopausal transition, and to investigate which health factors, life style and socio-
economic factors that were associated with frequency of symptoms. Another aim was to 
determine the association between symptoms and self-rated health. We also wanted to 
investigate the use of HT in the Cohort; factors associated with use of HT and to which 
extent the use of HT were in line with the Norwegian 2003 recommendations. Finally, we 
wanted to study if symptoms reappeared after cessation of HT.
The Cohort consisted of 2229 women aged 40-44 at baseline, and the women have 
received almost identical questionnaires approximately every second year. The material 
used in this study cover the first seven questionnaires (Waves 1 – 7; 1999 - 2010). Data 
for 2002 women (90 %) were eligible for analyses, and the results are published in Paper 
III and IV. 
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In a longitudinal analysis, 36 % of the women reported daily hot flushes in one or more 
questionnaires, whereas 29 % did not experience hot flushes at all. The prevalence of 
daily hot flushes increased from 2 % at ages 41-42 to 22 % at ages 53-54.  Daily smoking 
and low education was associated with more hot flushes.  
The two-year incidence of new HT users dropped significantly from 8.2% in 2002 
to 4.3%  in 2004 and remained stable despite increasing prevalence of symptoms in the 
cohort. Self-reported health was good or excellent for a high proportion and remained 
stable in the same period. 29 % of the women reported use of HT during the observation 
period, and mean duration of HT use was 4.5 years. Odds of HT use were higher among 
women with daily hot flushes compared to those who never or rarely experienced them.
After HT cessation, hot flushes were still present and the frequency did not differ from 
the untreated controls.
Conclusions
Norwegian GPs were generally aware of available evidence of effects and side 
effects of HT after 2002, and observed the recommendations with respect to indications 
and contraindications. The doctors’ attitude to the question of whether the treatment 
implies medicalisation was more crucial for the advice they gave than their perception of 
indications, contraindications and the effects of treatment, and was also important in the 
assessment of indications and contraindications. Such factors should be addressed when 
new clinical guidelines or recommendations are implemented.
The proportion of menopausal female GPs who used hormone therapy themselves 
was substantially higher in 2004 than the average for the female population in the same 
age group. This finding may imply that menopausal female GPs regarded the individual 
risk of treatment as low, and that most of them found the benefits of treatment greater 
than the risks. The finding is in line with other surveys. However, little research has been 
done to clarify reasons for the increased HT use among doctors.
An important finding in HWC was that the prevalence of bothersome symptoms 
was lower than in most other international surveys. Among healthy women, daily 
smoking was an independent risk factor for experiencing daily menopausal symptoms. 
This finding should encourage women to stop smoking. 
Use of HT in the HWC was lower than documented in comparable Nordic and 
international studies for the same period. Even though the symptom burden increased for 
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every wave up to the last wave (Wave 7), the use of HT did not increase after 2002. Many 
women preferred to live without HT in spite of their bothersome symptoms. Those who 
reported most symptoms had higher risk for reporting bad or not so good health, but the 
symptom burden did not influence self-rated health in the cohort in general. Our study 
design does not allow inference as to whether individual women have been under-treated, 
but the stable distribution of self-rated health categories after 2002 does not indicate 
systematic under-treatment in the cohort. The indication for HT according to the 
guidelines is bothersome hot flushes with a negative influence on quality of life. Hot 
flushes was the strongest predictor for HT use, and together with the fact that self-rated 
health did not change in a negative direction, we conclude that HT use in HWC was 
largely in line with the recommendations.
In line with other findings, we found that symptoms reappeared in most women 
after HT cessation. Further research is necessary to clarify in more detail the duration of 
treatment which may be necessary for symptoms to ware off. 
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Norsk sammendrag 
Hormonbehandling av symptomer som er forbundet med menopausen og 
medikamentell forebygging av kroniske sykdommer etter overgangsalderen har blitt 
intenst diskutert de siste 5-6 tiårene, både i medisinsk fagpresse og i det offentlige rom.
Hormonbehandling (HT) var i 1990-årene preget av forebyggingsoptimisme, og 
behandlingen ble ansett som effektiv og trygg for å forebygge kroniske sykdommer hos 
postmenopausale kvinner. Dette gjaldt særlig osteoporose (beinskjørhet), men også 
hjerte-kar sykdom, urininkontinens, kognitiv svikt og demens. I tiårene forut for dette fant 
det sted en debatt internasjonalt og i Norge om hormonbehandling som eksempel på 
medikalisering av en naturlig livsfase hos kvinner. Behandlingen ble opprinnelig kalt 
”hormonerstatning” (engelsk hormone replacement therapy). Tanken var at 
postmenopausale kvinner hadde en hormonmangel som burde behandles. Den kritiske 
medikaliseringsdebatten forsvant mer eller mindre i løpet av 1990-åra, da 
hormonbehandling som forebygging kom i fokus.
I løpet av en kort tidsperiode rundt årtusenskiftet skjedde det en dramatisk endring 
av kunnskapsgrunnlaget for hormonbehandling av kvinner under og etter 
overgangsalderen. Resultater fra nye randomiserte kliniske forsøk og fra store 
epidemiologiske studier viste at HT ikke forebygger hjerteinfarkt og innebærer en økt 
risiko for brystkreft. Funnene førte til omfattende endring av retningslinjer for 
behandling, internasjonalt og i Norge. I følge de norske anbefalingene er indikasjonen for 
HT plagsomme hetetokter som medfører redusert livskvalitet, og behandlingen skal 
revurderes årlig.
Fastlegene i Norge forskriver omtrent halvparten av hormonbehandlingen og er 
viktige diskusjonspartnere for kvinner i denne alderen. Den første delen av denne 
avhandlingen, Allmennpraktikerstudien, handler om kunnskap og holdninger hos norske 
allmennleger om hormonbehandling etter at de nye studiene ble publisert og retningslinjer 
for behandling ble endret. Hvordan oppfattet legene sin egen rolle i forhold til å starte 
eller avslutte behandling, og hvordan vurderte legene risikoen ved behandlingen? Ga 
legene forskjellige råd til kvinnene, og i tilfelle – var disse forskjellene assosiert med 
faktorer i bakgrunn eller holdninger? Vi ønsket også å undersøke i hvilken grad 
kvinnelige allmennleger selv brukte eller kunne tenke seg å bruke hormoner.
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Et tilfeldig utvalg av 400 norske allmennleger fikk i mai 2004 tilsendt et 
spørreskjema med spørsmål om effekter, indikasjoner, kontraindikasjoner, oppfatning av 
rolle og oppfatning av risiko ved HT. 289 leger (72 %) besvarte skjemaet. Tre av 
spørsmålene var formulert som kliniske eksempler der legene ble bedt om å angi om de 
ville gi råd om bruk av HT eller ikke, og de kunne også gi egne kommentarer i fri tekst. 
Resultatene er publisert i Artikkel I og II i avhandlingen, og viste at flertallet av 
allmennlegene var kjent med den tilgjengelige dokumenterte kunnskapen om effekter og 
bivirkninger av HT. De fleste anga at de fulgte gjeldende anbefalinger med hensyn til 
indikasjoner og kontraindikasjoner. Et stort flertall av allmennlegene var enig i at HT 
øker risiko for brystkreft, at behandlingen ikke forebygger hjerteinfarkt og at plagsomme 
hetetokter er den viktigste indikasjonen for behandling. 14 av 17 (82 %) kvinnelige 
allmennleger som var i eller etter overgangsalderen anga at de brukte eller hadde brukt 
HT. Undersøkelsen viste også at et flertall av legene hadde tiltro til mer uspesifikke og 
mindre dokumenterte effekter av HT, slik som positiv effekt på seksuallivet og at HT 
motvirker aldring av hud. De anså allikevel ikke dette som viktige indikasjoner for 
behandling. Legene ble spurt om de mente at HT innebar en uheldig medikalisering av 
kvinners overgangsalder.  En tredjedel av legene var enig i påstanden, noe flere (44 %) 
var ikke enig mens en fjerdedel var nøytral.  Ingen av bakgrunnsvariablene (f.eks. alder 
eller kjønn) predikerte standpunktet legene inntok til dette spørsmålet. Et viktig funn var 
at legene var tydelig delt i spørsmålet om å anbefale behandling eller ikke i de kliniske 
eksemplene. Holdning til HT bruk, belyst ved spørsmålet om medikalisering var den 
viktigste faktoren som predikerte anbefaling om å bruke eller ikke bruke HT, mens 
oppfatning av indikasjoner, effekt og risiko ved behandlingen spilte mindre rolle. De som 
var uenige i påstanden om medikalisering var mer tilbøyelige til å anbefale behandling. 
I den andre studien, Kvinnekohorten i Hordaland, var målsettingen å beskrive det 
naturlige forløpet av overgangsalderen og bruk av hormoner i en kohort av friske kvinner.  
Hvilke helse-, livsstils- og sosioøkonomiske bakgrunnsfaktorer er assosiert med 
hyppighet av symptomer, og er det sammenheng mellom symptomer og egenrapportert 
helse? Vi ønsket også å undersøke bruk av hormoner i kohorten, hvilke faktorer som var 
forbundet med hormonbruk og i hvilken utstrekning bruken var i samsvar med norske 
anbefalinger. Til slutt har vi ønsket å undersøke om symptomer kom tilbake etter at 
hormonbehandlingen ble avsluttet.
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Kohorten besto av 2229 kvinner som var i alderen 40-44 år ved oppstart, og 
kvinnene har mottatt spørreskjema årlig eller hvert annet år fra 1999 til 2010. Data fra 
2002 kvinner (90 % av kohorten) ble brukt i analysen, og resultatene er publisert i 
Artikkel III og IV i avhandlingen. 
I den langsgående analysen anga 36 % av kvinnene daglige hetetokter og mye 
plager i en eller flere runder, mens 29 % av kvinnene anga lite eller ingen hetetokter 
overhodet. Forekomst (punkt-prevalens) av daglige hetetokter økte fra 2 % i alderen 41-
42 år til 22 % i alderen 53-54 år. Røyking (registrert ved oppstart eller senere) og lav 
utdanning var forbundet med økt forekomst av daglige hetetokter i løpet av 
overgangsalderen. 
Toårs insidens av HT-bruk (nye brukere, ikke bruk i forrige runde) sank fra 8,2 % 
i 2002 til 4,3 % i 2004 og forble stabil på dette nivået på tross av økende symptomer blant 
kvinnene. 29 % av kvinnene anga at de hadde brukt HT i løpet av observasjonsperioden. 
Gjennomsnittlig varighet av bruk var 4,5 år. Den viktigste faktoren som var forbundet 
med bruk av HT var opplevelse av daglige hetetokter. For de fleste kom symptomene 
tilbake etter å ha sluttet med HT, og forekomst av symptomer var da ikke forskjellig hos 
brukere og ikke-brukere.
Konklusjon
Norske allmennleger var generelt godt oppdatert om kunnskapsgrunnlaget for HT 
etter 2002. Legens holdning til spørsmålet om medikalisering var mer avgjørende for de 
råd som ble gitt enn holdning til risiko, indikasjoner og kontraindikasjoner, og hadde også 
betydning for vurderingen av indikasjoner og kontraindikasjoner. Det kan tyde på at slike 
holdningsfaktorer er av stor betydning når nye behandlingsråd eller retningslinjer skal 
implementeres.
Andelen kvinnelige allmennleger som bruker HT var fortsatt høy i 2004 
sammenliknet med kvinner generelt i samme aldersgruppe. Funnet kan innebære at 
kvinnelige allmennleger anser at den risikoen de selv løper ved å bruke HT er lav, og at 
de fleste av dem anser at fordelene ved behandlingen er større enn risikoen. Tilsvarende 
funn er gjort også i andre land, men er i liten grad blitt gjenstand for ytterligere forskning.
Et viktig funn i kvinnehohorten var at forekomsten av plagsomme symptomer var 
lavere enn i de fleste sammenliknbare internasjonale undersøkelser. Blant friske kvinner 
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var daglig røyking en risikofaktor for å bli plaget med hyppige hetetokter, og funnet 
burde oppmuntre til røykeslutt.  
HT-bruk blant norske kvinner under og etter overgangsalderen var lavere enn 
dokumentert i andre nordiske og internasjonale studier i den samme perioden.  Selv om 
symptomene øker helt fram til siste registrering (runde 7), økte ikke HT-bruk i kohorten 
etter 2002. Mange kvinner foretrakk åpenbart å leve uten HT på tross av hyppige plager. 
De som var mest plaget rapporterte hyppigere dårligere helse, men symptombyrden 
influerte ikke på selvopplevd helse i kohorten som helhet.  Utformingen av vår studie 
tillater ikke slutninger om behandlingen av den enkelte kvinne, men det at selvopplevd 
helse ikke endret seg i negativ retning taler imot systematisk underbehandling av 
kvinnene. Indikasjonen for HT er ifølge retningslinjene plagsomme hetetokter som fører 
til dårlig livskvalitet.  Hyppige hetetokter var den viktigste faktoren som predikerte HT 
bruk, og dette sammen med at egenvurdert helse ikke endret seg i negativ retning 
innebærer at vi kan konkludere med at bruken av HT i det store og hele var i samsvar med 
norske terapianbefalinger. 
Ytterligere forskning er nødvendig for å klarlegge mer detaljert hvor lenge 
behandlingen må vare før symptomene er over for de fleste, dersom den starter omkring 
menopause alder. 
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Definitions and abbreviations 
Definitions of the menopause
In everyday language, the menopause means end of menstruation – that is the 
cessation of regular or irregular vaginal bleeding and the end of the fertile ability– and is 
experienced by every woman reaching that age. The aging process of the ovum and the 
ovarium is accompanied by and determined by several hormonal changes, and is not yet 
fully understood and characterized. The term climacterium is used somewhat imprecise to 
include the period from the beginning of menopausal symptoms and more irregular 
bleeding occur, until bleeding has stopped and the symptoms have more or less 
disappeared. In order to communicate and discuss the process and the symptoms more 
precisely, it has been necessary to apply more precise definitions on the stages of female 
reproduction. The WHO issued a definition of menopause in 1981, later revised and 
evaluated by an international group of researchers in Korkylampi, Finland in 1986 1. In 
this definition, the natural menopause called Final Menstrual Period (FMP) was defined 
retrospectively after 12 months of amenoré. Later revisions by the WHO Scientific group 
in 19962 have added criteria to the definitions in order to clarify the nomenclature used in 
international research. The latest achievements have been proposals from the 
International Menopause Society in 1999 and the definition adopted by the Stages of 
Reproductive Aging Workshop (STRAW definition), Utah, USA 2001 (fig. 1)3. Here, the 
menopausal transition is divided in two stages and covers a variable space from the cycles 
become irregular (> 7 days different cycle length) until FMP occur. The early 
postmenopause runs four years from FMP and is followed by the late postmenopause. 
The term perimenopause includes the menopausal transition and the first year after FMP, 
and will for many authors cover the same idea as the concept climacterium.
The definitions below includes recommendations by the WHO in 1996 as well as
the IMS-proposed addition of the term climacteric2,4.
1. Natural menopause is defined as the permanent cessation of menstruation 
resulting from the loss of ovarian follicular activity. It is recognized to have 
occurred after 12 consecutive months of amenorrhea, for which there is no other 
obvious pathologic or physiologic cause. Menopause occurs with the final 
menstrual period (FMP), which is known with certainty only in retrospect  > 1
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year after the event. An adequate independent biologic marker for the event does 
not exist.
2. Perimenopause includes the period immediately before the menopause (when the 
endocrinologic, biologic, and clinical features of approaching menopause
commence) and the first year after menopause. WHO advise the term climacteric 
to be abandoned to avoid confusion.
3. Menopausal transition covers a variable time space from the cycles become 
irregular (> 7 days different cycle length) until FMP occur.
4. Postmenopause is defined as the period dating from the FMP, regardless of 
whether the menopause was induced or spontaneous.
5. Induced menopause is defined as the cessation of menstruation that follows either 
surgical removal of both ovaries (with or without hysterectomy) or iatrogenic
ablation of ovarian function (e.g., by chemotherapy or radiation).
6. The climacteric is the phase in the aging of women marking the transition from 
the reproductive phase to the nonreproductive state. This phase incorporates the 
perimenopause by extending for a longer variable period before and after the 
perimenopause5 6.
7. Premature menopause ideally should be defined as menopause that occurs at an 
age > 2 standard deviations below the mean estimated for the reference 
population. In practice, in the absence of reliable estimates of the distribution of 
age at natural menopause in populations in developing countries, the age of 40 
years is frequently used as an arbitrary cut-off point, below which menopause is 
said to be premature.
The definition of menopause (and FMP) is in the thesis based on the self-reported 
cessation of menstruation, and this fact leads to several methodological problems. An 
(unknown) proportion of women experience menstrual bleedings after 12 months of 
amenorrhea, and this may result in a reassessment of FMP among these women. Also, the 
use of contraceptives (gestagen pills or IUD) often leads to cessation of menstruation 
without the other symptoms indicating that menopause has occurred. How women with 
simple hysterectomy should be regarded has not been clearly stated by the WHO 
definition. Therefore, these women are often excluded in studies or treated in separate 
groups7. It is also worth noting that several studies indicate that women’s self-rating of 
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menopausal state often disagree with the menstruation-based definition7-13. In 
epidemiological studies, investigators have chosen different strategies to overcome this14.
In our study, we decided to exclude the women who had undergone oopherectomy and/or 
hysterectomy, since we did not have access to hospital data, follow-up interviews or other 
ways to ensure if both ovaries or only one had been removed. In addition, studying the 
natural course of menopause was our primary interest. FMP and menopausal status were 
in our study established by means of last self-reported menstruation at least 12 months 
before the questionnaire was filled in, and no later reporting of menstruation.
Figure 1. STRAW definition of the normal reproductive aging in women. Reprinted with 
permission from Fertility and Sterility, 2001, Vol 76, No 5, page 875.
Abbreviations
AR Absolute risk.
ARR Absolute risk reduction (risk difference or excess risk) is the difference 
between the control group’s event rate (CER) and the experimental group’s 
event rate (EER). The difference is usually calculated with respect to two 
treatments A and B, with A typically a drug and B a placebo.
BMI Body Mass Index: weight(kg)/height(m)2.
CER Control event rate: the number of events in the control group divided by 
the number of participants in the control group. 
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CHD Coronary heart disease
CONOR Cohort of Norway. A collection of health data and blood samples from 
several Norwegian health surveys with the purpose of investigating the 
causes of disease. Among these are HUSK and HWC.
CVD Cardiovascular disease
DDD Defined daily dose of a medication, according to international 
pharmaceutical standards.
E2 Estradiol.
EER Experimental group event rate. The number of events in the experimental 
group (typically the treatment group in clinical trials) divided by number in 
the same group.
EMS European Menopause Society
ET Estrogen Therapy: Treatment with estrogen only for women without an 
intact uterus.
FSH Follicle stimulating hormone.
GP study The general practice part of the Thesis: Questionnaire sent to 400 
Norwegian GPs in April 2004.
GP General Practitioner / Family Medicine Practitioner.
HERS Heart and Estrogen/progestin Replacement Study.
HF Hot flushes.
HRT Hormone Replacement Therapy: Treatment with estrogen and/or estrogen-
progestogen combination of peri- and postmenopausal women, in later 
years replaced by the notion HT (underneath).
HT Hormone therapy: Treatment with systemic estrogen and/or estrogen-
progestogen combinations for women during perimenopause and/or later.
HUSK The Hordaland Health Study.
HWC study The Hordaland Women’s Cohort part of the Thesis. The Cohort started in 
1999, with baseline data from HUSK (Helseundersøkelsen i Hordaland) in 
1997-98 when the women was aged 40-44 years. In 2010, the Cohort had 
finished seven questionnaires and reached the age of 53-57 years.
HWC The Hordaland Women’s Cohort. 
IMS International Menopause Society
LH Luteinizing hormone.
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MWMHP Melbourne Women’s Midlife Health Project, an Australian Cohort study.
MWS Million Women Study.
NAMS North American Menopause Society
NDA Norwegian Drug Agency [Legemiddelverket].
NHD Norwegian Health Directorate [Helsedirektoratet].
NIPH Norwegian Institute for Public Health [Folkehelseinstituttet].
NMA Norwegian Medical Association [Den norske legeforening].
NNH Number needed to harm. The reciprocal value of absolute risk increase 
(1/ARI).  The number that must be treated to cause one additional event 
(side effect, death or disease), compared with no treatment. F.ex. 125 
women must be treated with HT in 10 years to cause one additional case of 
breast cancer. 
NNT Number needed to treat. The reciprocal value of absolute risk reduction 
(1/ARR). The number who must be treated by a given therapy to avoid one 
pre-defined event (death or disease), compared with no treatment. 
NSAM Norwegian College of General Practitioners [Norsk Selskap for 
Allmennmedisin], from 2006 NFA – [Norsk Forening for 
Allmennmedisin].
QoL Quality of Life.
RRR Relative risk reduction: calculated by dividing the absolute risk reduction
by the control event rate (CER).
S/NS Sweats/night sweats.
STRAW Stages of Reproductive Aging Workshop. An expert group putting forward 
a refined definition of the stages of the female reproduction and 
menopausal transition (STRAW definition), USA 2001.
SWAN Study of Women’s Health across the Nation, a US based cohort study.
Regular GP Scheme. The health reform carried out in 2001 in Norway, giving every 
citizen the right to be listed as a patient by a GP who is employed by or 
having contract with the local municipality.
VMS Vasomotor symptoms: hot flushes and sweats, night sweats.
WHI Women’s Health Initiative Study.
WHO World Health Organization.
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Preface 
In my clinical and professional work as a general practitioner (GP), I was for 
many years interested in the broad field of prevention, especially prevention of 
cardiovascular disease. This led me in contact with groups in the Norwegian College of 
General Practitioners (NSAM), and the discussion which took place in the 1990s and 
onward on the problems of medicalisation of large proportions of the population. During 
these years, there was an ongoing debate regarding individual-oriented prevention of 
cardiovascular disease, which was the main cause of death in the Norwegian population 
from 1960 and onwards. The controversies covered several areas, including the question 
of which risk level should be the threshold for initiating medical interventions, and what 
was the most cost-effective treatment. Often, doctors from primary care were opposed to 
secondary care specialists, and an important reason for this was the differences in 
perspectives. The GPs are confronted with mainly healthy people, and in the field of 
prevention should be more concerned about the factors which keep people healthy, while 
the organ specialist are more concerned about the diseases and the factors that may lead 
to sickness and death. In this field, also the industry plays an important role. Individual-
oriented prevention is an enormous market. The greater proportion of the population that 
can be included in the market plans, the greater is the potential for profit.
As a member of  the Reference Group for Cardiovascular Disease Prevention in 
The Norwegian College for General Practitioners, (I was also a member of the board and 
later also the president of the College) I was engaged in the work to produce sustainable 
guidelines for prevention in Primary Care15-18. The board was concerned about the “risk 
epidemic” in a broader sense and initiated “The Risk Project”19, supported by the Health 
Minister at that time. The Risk Project was an effort to focus on the side effects following 
interventions to reduce risk for future disease in the population. 
For me, this also led to an interest in other areas of medicine where arguments for 
prevention of disease and health maintenance have been used to prescribe medication. An 
outstanding example of this is hormone therapy of women during and after the 
menopause. 
In 2002, new evidence emerged which profoundly changed the scientific basis of 
hormone treatment of the postmenopausal woman. The results from the North American 
Women’s Health Initiative study showed that oestrogen and oestrogen-gestagen treatment 
did not prevent cardiovascular disease, as had been argued during the 1990s20. Before this 
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evidence emerged, several indications had been given to advocate the prescription of HT, 
and there were very few arguments against the use of hormones. Many GPs in Norway
had been a little reluctant, but the concerns about side effects of the treatment had 
gradually diminished over the years, with the growing evidence from epidemiological 
studies about the benefits of the treatment. Now – quite suddenly – the evidence changed. 
After the WHI results were published, there were some media reports and 
discussions about the treatment in Norwegian newspapers, but the discussions were not 
very long-lasting. In the autumn of 2002, a question was raised in the Internet discussion 
forum for Norwegian GPs, EYR: “How does Norwegian GPs address the question of 
hormone treatment of the menopause?”  The person behind this demanding question was 
Ivar Aursnes, professor of Pharmacotherapy at the University of Oslo, and nobody could 
answer his question. I discussed it with my co-authors of the first article, Per Hjortdahl at 
the Institute for General Practice and Community Medicine and GP Elisabeth Swensen, 
who had been active in NSAM’s Risk Project.
In the first phase of the project, I wanted to find out how the GPs in Norway dealt 
with the new evidence. What did they think about indications, contraindications and risk
after the publishing of the WHI results, and what kind of advice did they give to the 
women? This led to a questionnaire survey sent to 400 Norwegian GPs in 2004, the GP 
study of the project. Two articles were published in the Journal of The Norwegian 
Medical Association 21,22.
This first phase of the project led to an interest in the women themselves: Do we 
have valid information about the natural course of menopause among Norwegian women? 
How often and how long do women experience bothersome symptoms? Who use HT and 
for what, and have new guidelines changed practice? These are aspects of the menopause 
where precise information is valuable for the GP when giving advice to women in this 
age group. The second phase of the project consists of data from the Hordaland Women’s 
Cohort, a population-based cohort of 2229 women in the Hordaland County of Western 
Norway. In 2010, the Cohort had finished seven questionnaires and reached the age of 53-
57 years. It was possible for me to contribute to the questionnaire in the seventh wave of 
the Cohort. Detecting symptoms and symptom burden during the menopausal transition, 
and use of medication among healthy women during this period of life were some of the 
aims of the Cohort.
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After the publishing of the WHI results in 2002, HT had been continuously
discussed in international medical journals, and new evidence has emerged also in the 
field of menopausal symptomatology. Although the evidence has been emerging, there 
are still many controversies and challenges for the clinicians. It is my hope and ambition 
that the results from these Norwegian surveys will contribute to the knowledge and
clinical work done  by the GPs and other doctors working with women in this age group,
and for the women themselves.
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Background 
The written knowledge of female menopause goes back to the ancient Greeks. The 
Greek word menopause consists of the word “menos”, which means “month”, and 
“pause”, which means “cessation”. The literary meaning is “the cessation of monthly 
periods”. The word “climacterium” refers to steps in a ladder. During the history, there
has been diverging perspectives regarding the menopause: should it be viewed as a step 
“up” or a step “down” the ladder? Previous medical literature had rather curious and 
speculative descriptions of the menopause, as this from 1887:
“The ovaries, after long years of service, have not the ability of retiring in 
graceful old age, but become irritated, transmit the irritation to the abdominal ganglia, 
which in turn transmit the irritation to the brain, producing disturbances in the cerebral 
tissue exhibiting themselves in extreme nervousness or in an outburst of actual insanity.”
(Farnham AS, cited in 23).
In her dissertation, the Swedish GP Helene Ekström14 notes a shift of the view of 
the female climacteric in the last part of the 19th century. In the 18th century, physicians 
believed that the cessation of menstruation preserved the health of older women, and hot 
flushes were by some scientists seen as beneficial. The term “menopause” was introduced 
by the French physician Gardanne in 1821, at a time when the specialty of gynecology 
and obstetrics was formed in Europe. From the mid of the 19th century an increasing 
number of diseases and bothersome symptoms and conditions became associated with the 
menopause, and a perception of menopause as a negative event became prevalent24.
Following the isolation of sex hormones in the 1920s and the syntetication of oestrogen in 
1938, the menopause was defined as a hormone deficiency state and ultimately a 
disease25,26. Addressing the general public in 1966, the American gynecologist Robert 
Wilson in his famous book “Feminine forever” started the first wave of HT, at that time 
called hormone replacement therapy (HRT)27. The notion of menopause as a deficiency 
state, in which hormones should be replaced, came to dominate the medical discourse of 
menopause in the Western world. Naturally, this deficiency state also became associated 
with a wide variety of symptoms and diseases.
In addition to the biomedical perspective on menopause, many authors from the 
1980s and onward add the sociocultural perspective, emphasizing the diversity of 
symptoms and experience of menopause in different parts of the world28. In 1986, an 
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international group of researchers met in Korpilampi, Finland, to discuss definitions of 
menopause and future research. According to this workshop, menopause is a biocultural 
event and modifiable by factors within the environment1. The story women tell about 
menopause, both in regards to symptoms, the menstrual pattern and other aspects, differ
between cultures. Interpretation of epidemiological research based on western notions 
about menopause is not necessarily valid in other cultural settings. For example, the  hot 
flushes symptoms which are central in the western story of menopause, were sparsely 
reported among Japanese women29.
These perspectives have been brought forward in the US based SWAN project, 
where symptoms and health factors among women of different ethnic origin in USA have
been studied30. The sociocultural perspective argues that the menopause not only should 
be viewed as a biological process inside the individual woman, with cessation of 
menstruation as the hallmark, but that menopause can be experienced and presented in 
many different ways, according to local beliefs and experiences28. The sociocultural 
perspective focus on the process of aging per se, thus challenging the biomedical focus on 
effects of hormone depletion. These perspectives are important in the broad discussion of 
menopause, but also in a clinical setting, as most doctors see women with different ethnic 
background in their daily practice. An ideal of general practice is the holistic perspective, 
as general practice “deals with health problems in their physical, psychological, social, 
cultural and existential dimensions”31. Taking other perspectives than the biomedical 
into the consultation can lead to lesser focus on pharmacological interventions.
Hormonal and tissue changes during the menopausal transition.
The hypothalamus - pituitary – ovarian hormonal axis is central in the mechanism 
of menopause, and is described extensively in the literature. Since it is not the theme for 
the dissertation, only a short outline is given here:
The starting point of the menopausal process seem to be depletion of ovums in the 
ovaries32. The start of menopause is assumed to be programmed, starting around ages 45-
50 in all regions of the world. It is also a specific process for human beings, and does not 
seem to take place in other mammals, except perhaps some female toothed whales32. This 
contrasts the more gradual, slowly emerging natural aging of other tissues and species. 
The ovarian hypothesis suggests that most events in female reproductive life are directed 
by the size and quality of the follicle store. The crucial factors determining the start of 
menopause are the number of oocytes formed during intra-uterine life and the rate of 
29
depletion of the follicle store (through maturation of ovums and degeneration of germ 
cells).
The hormonal changes during menopause are described in increasing details over 
the last decades33-37. Both estradiol (E2) and the peptide hormones Inhibin A and Inhibin 
B are produced in the ovarian granulosa cells, and the amount produced is influenced by 
the pituitary hormones FSH (follicle stimulating hormone) and LH (luteinizing hormone). 
Declining levels of Inhibin B (and A) is followed by increasing levels of FSH, and marks 
the start of the menopause33. LH levels also increase, but less marked compared to FSH. 
Approximately two years prior to final menstruation date (FMP), the levels of FSH start 
to rise and levels of the sex hormone estradiol (E2) begin to fall. The testosterone levels 
do not change significantly during the perimenopause37. While the postmenopausal 
production of estradiol and progesterone virtually ceases, the ovary continues to secrete 
testosterone from the interstitial cells38. In summary, there are great variations and 
complexity in hormone levels during the menopausal transition, and measurements of 
FSH or estriol are generally not reliable for characterizing the menopausal stages in the 
individual women37.
Menopause research
Over the years, a wide variety of symptoms have been attributed to the 
menopause. Besides the classical vasomotor symptoms (hot flushes and sweats/night 
sweats), urogenital symptoms like vaginal dryness, pain during intercourse (dyspareunia)
and varying degrees of incontinence are common. Sleeping problems, anxiety and 
depression are described, as well as fatigue, muscle and joint pain, drying of the skin, loss 
of energy, loss of libido and many other symptoms and problems. Breast tenderness is a 
symptom that decreases during the menopausal transition. This plethora of symptoms is 
reflected in several “check lists” and instruments for quantification of symptoms of the 
menopause, f.ex. Kuppermann index, Greene Climacteric Scale, Women’s Health 
Questionnaire, Menopause Rating Scale and others39-41.
The variety of symptoms that has been attributed to the menopausal transition was 
driven by a combination of researchers exploring a “new” field of medicine and a 
pharmacy industry promoting HRT for these complaints. The concept of a “menopausal 
syndrome” was introduced, to embrace many physical and psychological symptoms and 
diseases which could be linked to the menopausal transition and the age beyond it42.
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The studies of symptoms, health and health complaints during menopause have 
raised a number of important methodological considerations. In cross-sectional studies, it 
is not possible to disentangle age effects from effects of menopausal stage, or adjust for 
premenopausal health factors that can influence the results. In some prospective studies, 
age has been used as a proxy for menopausal stage. In that case, separation of the effect 
of aging from hormonal or physiological changes taking place during the menopausal 
transition and postmenopause is impossible. Secondly, the representativity of the selected 
participants is important. In many studies, self-recruitment based on symptoms has been 
used. Typical examples came from women seeking help for menopausal complaints. 
Studies based on representative, community based samples are important when the aim is 
to describe symptoms in the normal, healthy population. In addition, important
confounding factors have to be dealt with, depending on the outcome of interest. As an 
example: when depression or psychological symptoms are addressed, the influence of 
age, important life events and vasomotor symptoms must be controlled for in the model. 
Menopausal symptoms were typically studied in cross-sectional studies, many of 
which from menopause clinics, and the external validity of these studies was disputed43.
From late 1980s, longitudinal, population based studies were undertaken, contributing to 
more valid knowledge.  Important contributions came from the Massachusetts Women’s 
Health Study11. According to this study, the median age of menopause is 51.3 years and 
the normal range of the perimenopause is four years.  The Australian Melbourne 
Women’s Midlife Health Project (MWMHP) explored associations between natural 
hormones and menopause, and found that the symptoms related to the menopausal 
transition were hot flushes, night sweats, dryness of the vagina and the disappearance of 
breast tenderness12,44.  The Canadian Manitoba Project studied the relationship between 
the menopausal transition and depression and other psychological factors45,46. The study 
demonstrated that other life events like children leaving home, old parents getting sick or 
died, and other stress factors related to family life or diseases were more important factors 
associated with depression among women in these years. Also, results from British and 
Swedish cohort studies have contributed to more reliable results47,48. Review articles 
from 1992 and onwards have summed up the results30,49-52. Results from these studies 
vary considerably on many parameters, e.g. menopausal age, degree of symptoms, 
duration of symptoms, and medication use53-55. Cultural and racial/ethnic differences may
also explain some of the differences found in these studies54,56.
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The Norwegian Menopause Project, led by the psychologist Arne Holte was a 
prospective cohort consisting of 1886 women, randomly selected in the Oslo area and 
followed from 1982 to 198657. The aim of this project was to study psychosocial factors 
and the menopause in a representative, prospective cohort of healthy women. Findings 
from this study included a factor analysis confirming that the vasomotor symptoms were 
the symptoms most consistently associated with  menopause10.  Later, a second survey 
was derived from the cohort, consisting of 200 women randomly selected and followed 
from 1987 to 199233,35,36,58,59. The aim of the follow-up project was to study the hormonal 
changes during the menopausal transition, and to establish the relationship between 
hormones, gendered personality disposition and subjective complaints (such as hot 
flushes, musculoskeletal pain and psychological distress). 59 women formed the final 
substudy group in this study.  Before menopause, hot flushes were associated with low 
levels of estradiol and high levels of FSH, while no such association was obvious later, 
and the hormonal changes observed in the women were difficult to assign to symptoms. 
Important contributions from the NMP were the methodology of a randomly selected,
community based cohort design and the statistical methods used to separate symptoms 
due to physiologic changes during the menopausal transition from symptoms due to
aging.
Symptoms during the menopausal transition
The biological mechanism of VMS 
The vasomotor symptoms involve two biological systems: the core body 
temperature regulatory center in the central nervous system, and the peripheral
vasculatory system of the body, regulated by the sympathic nerve system60.
The core body temperature is regulated between an upper threshold when 
sweating occurs and a lower threshold when shivering occurs. Sweating lowers the core 
temperature through heat loss when sweats vapor off from the body surface. The 
shivering creates heat through muscle work. Laboratory research has shown that HF often 
is proceeded by elevations in core body temperature61. Hot flushes are triggered when the 
core body temperature crosses the upper limit of the thermo neutral zone, which seems to 
be greatly narrowed in women with bothersome symptoms62. According to the same 
study, these women also have elevated levels of central noradrenergic activation 
compared to asymptomatic women. Peripheral estrogen levels are not associated with hot 
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flushes, and this fact supports the theory of a central nervous mechanism of HF. HF 
frequently occurs during sleep, and the researchers also found that HF in the second half 
of the night occurred after awakenings or arousals. Estrogen, clonidine DQĮ2-adrenergic 
agonist that reduce central sympathetic activity) and SSRI decrease sympathetic activity
and have been shown to widen the narrowed thermo neutral zone of symptomatic 
women, while tryptophan depletion and yohombine DQĮ2-adrenergic antagonist) tend to 
further narrow this zone and provoke VMS60.
The role of the peripheral vascular system in VMS is to induce heat loss by 
vaporization of sweat and vasodilatation. This is controlled by cholinergic sympathetic
neurons, but also local mechanisms may play a role. 
Taken together, vasomotor symptoms (VMS) are body temperature dysfunctions 
that occur due to changes in gonadal hormones, but the exact mechanism by which the 
changing levels of hormones exert their effects on the temperature regulation is not fully 
understood63.
Prevalence and incidence of VMS. 
According to a recent meta-analysis, prevalence of symptoms peak 1-2 years after 
final menstrual period (FMP), when approximately 50 % (95% CI 42-58%) experience 
bothersome symptoms55. At the same time, many women experience hot flushes many 
years before FMP, or they start to get symptoms several years after. The variety, 
frequency, duration and burden of symptoms vary from individual to individual.
The symptoms are reported by women all over the world, but the prevalence and 
demand for treatment differ between regions and cultures, and also between women of 
different ethnic background living in the same society or between countries in the same 
region of the world. The findings from a number of longitudinal cohort studies and cross-
sectional studies are summarized in Table 1. The differences found in these studies 
probably have many reasons, including methodological such as different sample size, 
different populations with different representativity, and use of different questions and 
measuring tools. A number of factors have been shown to be associated with VMS, 
including genetic disposition, cultural and social factors, psychological factors, attitudes 
to menopause, stress, life style, diet, medication use etc., and very few of the surveys 
control for these factors.
33
Table 1. Prevalence of bothersome hot flushes and vaginal dryness in different regions of
the world, according to a number of population based cohort and cross-sectional studies.
Region Study N Age span 
(yr)
Prevalence HF *
(bothersome)
vaginal
dryness
Europe
Finland Moilanen 201064
Cross-sectional
1,427 45-64 38-54 %
Norway
(NMP)
Holte 199157
cohort
1,886 45-55
5 yr follow 
up
45 % 22 %
Holte 199258
subcohort
200 45-55
5 yr follow 
up
Very troubled 12 %
Denmark Køster 200265
cohort
548 40-60
20 yr 
follow up
31-46-68 % (pre-,
peri- and post-)
Sweden Rödström 200248
cohort
1,462 38-60
22 yr 
follow up
68 % (early post)
UK Hunter 201166
cross-sectional
10,418 54-65 54 % VMS
Rating 4/10
Holland Maartens67 6,648 47-54 12-66 % 20-45 %
Australia
MWMHP Dennerstein
200044 cohort
438 45-62 39 % (any up to 52
%)
3-47%
Asia
Malaysia Dhillon68
Cross-sectional
326 45-60 35-53 % 39-55 %
America
USA
SWAN 
Gold  200650
Cohort
3,198 42-59
Total
20 – 57 %
White 5-35 %
Afro-
American
12-50 %
Hispanic 12-30-12 %
Chinese 4-25-48 %
Japanese 4-22-18 %
MWHS McKinlay 199211
cohort
2,570 45-60 30-50 %
Penn 
OAS
Freeman 200152
cohort
438 35-47 26 % (any up to 79 
%)
Canada
Manitoba    
Kaufert 199269
cohort
469 45-55 14-40 %
*Prevalence from pre- through peri- to postmenopause
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In Table 2, results from a systematic review and 2 meta-analyses are 
summarized53-55. The frequency of bothersome VMS shows great variations. Most of the 
European surveys report VMS (hot flushes) in 50-75 %. Since the burden of symptoms 
are usually not reported, and results are summarized both from longitudinal and cross-
sectional studies, it is difficult to compare64-67.
Table 2. Vasomotor symptoms around the world. Results from a meta-analysis and 2 
systematic reviews.
No of 
studies
Longitu
dinal
N Peak Duration Bothering 
VMS
Politi 200855 10 2 35,445 FMP+1 
year
FMP+8 
years
Up to 53 %
Woods 200553 12 12 18,255 FMP+ 1
year
Up to 40 %
Freeman 200754
North America 12 18-46 %
Europe 11 73 % (preval)
East Asia 10 20-40 %
South East Asia 9 25-80 %
Australia 6 16-55 %
Latin America 6 0-67 %
South Asia 4 14-42 %
Africa 2 23-57 %
The question of when symptoms are most prominent during the menopausal 
transition has been evaluated in several of the longitudinal cohort studies. The cohort 
design is suitable for this question70. The SWAN study found that across all ethnic 
groups, there was a significant increase in symptom prevalence from premenopause until 
postmenopause, with a peak incidence in late perimenopause50. In the Australian 
MWMHP study, the frequency of bothersome hot flushes reached a maximum 
approximately two years after FMP, and 75 % of the cohort reported bothersome hot 
flushes at some time during the transition12. In this study, premenstrual complaints before 
the transition were associated with more VMS and other symptoms.
The duration of symptoms is not established, and probably the variation of 
duration is very great, as it is for prevalence per se. From the Australian Cohort study 
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MWMHP, the average duration of vasomotor symptoms was more than 5 years, longer 
than previously reported49. In a recent cross-sectional British survey among women aged 
54-65, 90 % had experienced hot flushes/night sweats, with symptoms lasting on average 
10 years for 54 % of the women66.
The prevalence of symptoms reported in these studies is of course confusing, both 
for the clinicians and the women concerned. From the clinician’s point of view, the 
prevalence and duration of bothersome symptoms and degree of influence on quality of 
life are the most relevant factors. The lack of relevant information regarding this in many 
of the studies mentioned above is a serious limitation in menopausal research.
 
Factors associated with VMS. 
Factors associated with symptom prevalence and symptom burden are analyzed in 
a number of studies30,48,60,64,71-74.
Age and menopausal stage 
VMS are linked to age and menopausal stages. Several studies find that peak 
prevalence of symptoms appear in late perimenopause or in early postmenopause73,75. In a 
recent review including two longitudinal and eight cross-sectional studies with a total of 
35,445 participants, the proportion of women reporting VMS increased sharply from two
years before FMP and reached a peak prevalence one year after FMP55. According to 
these studies, the percentage of women reporting VMS returned to premenopausal levels 
approximately eight years after FMP. The median duration of VMS among symptomatic 
women was four years.
Also, the prevalence of vaginal dryness increase with age, but is not so closely 
linked to menopause. The overall prevalence of vaginal dryness in a Swedish study of 
5,990 women aged 46-62 years was 21 %, reaching 34 % in the oldest age group71. The 
SWAN study reports a lower prevalence of vaginal dryness but with the same relation to 
age, from 8 % in the 42-45 year old age group to 20 % in the 52-55 year age group73.
Smoking 
In several studies, smoking has been associated with more menopausal symptoms
72,73,76. However, this was not found in a Swedish cohort study of women aged 49-53
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years74, nor in a recent study from Finland64. Smoking have been found to have an anti-
estrogenic effect77, so an association between smoking and VMS during the menopausal 
transition is plausible.
Physical activity 
The data is diverging. A 2007 Cochrane review on effects of exercise on 
menopausal symptoms referred to a number of observational studies with inconclusive 
results78. Some studies report that physically active women have fewer VMS compared to 
less active64,72,73,79. On the other hand, several cross-sectional studies have not found any 
association between physical activity and VMS76,80. Also, a case-control study with 82 
cases and 89 controls did not find any association between physical activity before FMP 
and later symptoms81. The inconsistency of the results may have several reasons, e.g.
different ways of reporting physical activity (frequency, intensity, self-reported, 
measured, assessment compared to other etc). The majority of these surveys are cross-
sectional, so it is impossible to determine if women report fewer symptoms because they 
are active and feel better anyhow, or if women with more symptoms are less active 
because of their symptoms. According to a recent review, the role of aerobic exercise to 
reduce VMS is not established, but the evidence suggest that physical activity is 
associated with better QoL among symptomatic midlife women. Physical activity against 
menopausal symptoms is recommended by the North American Menopause Society and 
the Royal College of Gynecology and Obstetrics in the UK82.
Weight, BMI 
The role of BMI in relation to VMS is unclear82. Higher BMI are in some studies  
associated with less VMS, while other cross-sectional and observational studies report an 
association between higher BMI and more hot flushes73,81,83. In other, no association or 
fewer symptoms have been found84,85. Adrenal androgens is converted to estrogen in 
adipose tissue86, and higher BMI has therefore been thought to protect against hot flushes 
in the menopause. Again, the diverging results can be attributed to several factors, 
including the design (longitudinal or cross sectional, representativity), the way BMI are 
registered (self report or physical measurement), controlling (or not) for confounders and 
other risk factors, etc.
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Socioeconomic factors (income level, type of work, education) 
In the Australian MWMHP study, women reporting hot flushes at baseline were 
significantly more likely to not be in full- or part-time paid work72. In a cross-sectional
analysis from UK, higher education (above 18 years) was associated with lower reporting 
of hot flushes87. The Swedish Woman’s Health in Lund Area study also found a lower 
risk for hot flushes related to high education, and among risk factors for hot flushes were 
part-time employment and unhealthy life style71.
Other symptoms 
Symptoms which have been associated with hormonal loss and the menopause 
include depression and mood alterations, sleep disturbances, reduction of libido and other 
symptoms related to sexual function, aging of skin and loss of energy and vitality – all of 
these symptoms should be targeted by HRT according to Wilson27. So are these 
symptoms associated with or caused by the hormonal changes during menopause? The 
evidence from longitudinal studies is sparse. According to the Australian MWMHP 
study, the most important factors influencing the sexual function was the prior level of 
sexual function, losing or gaining a sexual partner, feelings toward a partner, and also 
estriol levels88.Sexual response decreased with age, and vaginal dryness/dyspareunia 
increased with lower levels of estradiol. Testosterone was not associated with the aspects 
of female sexual functioning measured in this study. Prior sexual function and partner 
issues had larger effects on women’s sexual function than hormonal factors89. Aging are 
associated with decline in sexual function in several studies, as well as the length of the
relationship with the partner90.
The diagnostic entity “female sexual dysfunction” with a suborder called 
“hypoactive sexual desire disorder” has been added to the American Diagnostic and 
Statistical Manual of Mental Disorders (DSM IV). Up to 43 % of the adult female 
population in USA are suffering from this condition, according to some enthusiastic 
researchers91. However, these conditions are controversial92, because it downplays the 
role of emotional and cultural factors, and does not encompass contemporary 
understanding of the complexity of women’s sexual responses93. Although some aspects 
of reduced sexual function can be attributed to medical conditions, like dyspareunia due 
to vaginal atrophy, many other aspects can be seen as sound adaption to altered life 
circumstances. 
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Is there a menopausal syndrome?
As mentioned above, the symptoms most consistently connected to menopause 
and the subsequent changes in hormonal status during the menopausal transition are the 
vasomotor symptoms (hot flushes and sweats/nights sweats) and vaginal dryness, and to 
some extent sleep disturbances 9,10,44,94,95. The many other symptoms and complaints that 
have been associated with menopause, like depression, fatigue, sleeping disturbances, 
musculoskeletal pain, decreasing sexual function etc are to a much lesser extent proven to 
be associated with menopausal stages and hormonal changes. Following this, the effect of 
HT on these symptoms is not established. Many assumed effects of HT, especially effects 
linked to sexuality, feminity and attractivity as a woman has been attributed to the notion 
that declining levels of oestrogen are the main cause of these common complaints, and 
not the result of aging per se. 
The proposal of a specific menopausal syndrome, consisting of a cluster of 
symptoms in addition to the vasomotor symptoms, was put forward in the 1950’ies42,96.
The existence of a syndrome has been debated internationally over many years, and is 
still questioned97. Diseases such as osteoporosis, cardiovascular disease and Alzheimer’s 
disease have also been associated with hormone loss among women in contrast to men, 
but have not been considered part of a menopausal syndrome. Several epidemiological 
studies conducting factor analyses are consistent as to the significance of VMS as a 
specific symptom complex associated with the menopause, separate from other somatic 
complaints or psychological symptoms10,98,99. The idea of a universal menopausal 
syndrome has now been rejected by most investigators in the field100,101.
Age at menopause
In a recent European cross-sectional study, the question of increasing age at 
menopause was raised102. The authors found a median age at natural menopause (women 
not undergoing surgery) of 54 year, considerably older than the median age of 50-51
years found in previous studies103,104. Factors associated with lower age at menopause in 
the SWAN study were current smoking, lower education, being separated or divorced, 
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non-employment and history of heart disease, while more children, prior use of oral 
contraceptives and Japanese ethnicity were associated with higher age103. In a Finnish 
study, the median age of menopause was 50 years in 1997 and 51 years in 2007. Current 
smoking was associated with lower age at menopause, and the difference between 
smokers and no-smokers was larger in 2007 than ten years earlier. Lower education was 
associated with lower age at menopause, and physical activity with higher age104.
Treatment of the menopause.
Medicalisation.
The term “medicalisation” was originally put forward by sociologists, such as 
Irving Zola and Peter Conrad, and the psychoanalyst Thomas Szasz105,106. Although 
controversial, it has gradually become accepted also by the medical profession, as a 
notion describing underlying trends in the relation between medicine and the culture and 
society. The definition from Wikipedia is useful to describe the concept: 
“Medicalisation is the process by which human conditions and problems come to be 
defined and treated as medical conditions and problems, and thus come under the 
authority of doctors and other health professionals to study, diagnose, prevent or treat.” 
(16.01.2012.)
The philosopher Ivan Illich brought the concept forward in his famous criticism of 
modern medicine "Limits to medicine: Medical nemesis" (1975)107. He argues that 
medicine actually harm people through the process of iatrogenesis: the doctor-caused 
disease or harm. He sees medicalisation on three levels: A clinical level (the doctor’s 
treatment cause side effects – often more harmful than the disease), a societal level 
(leaving the general public in the hands of the medical expertise to cope with life) and in 
a cultural (structural) context, where medical understanding of life processes take over for 
the traditional cultural explanations and beliefs.  
The modern treatment of menopause can be seen as a large-scale – may be the 
most extensive ever – example of medicalisation and doctor-driven iatrogenesis, 
rendering all the three levels of medicalisation:
1) The clinical level: Treatment with HT has caused hundred of thousands breast 
cancers in the western societies, and hundreds of thousands cases of thrombosis
and cardiovascular disease.
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2) The societal level: With the introduction of HT, menopausal symptoms should be 
treated by doctors, and not by the women themselves.
3) The cultural/structural level: The medical profession (or at least influential parts of
the profession) described the menopause and the aging of women as a “hormone
deficiency disorder” – not a natural phase in a woman’s life. 
History of hormone (replacement) therapy
The subheading illustrates the point: In the start of the HT era of the 1960s, the 
therapy was called hormone replacement therapy (HRT), simply because the intention 
was to replace the hormone which was gone lost. Recently, the notion has been changed 
to hormone therapy (HT), to take away the concept of deficiency and focus on treatment 
of symptoms.
Medical treatment of menopausal symptoms started in the 1930’ies, when
estrogens was isolated from the urine of pregnant women and became commercially 
available108. But it did not become in widespread use before it was introduced by the 
American gynecologist Robert A Wilson. His bestseller “Feminine forever” 27 started the 
era of hormone replacement therapy (HRT) in the Western world. In Norway, the 
gynecologist Eivind Myhre wrote a Norwegian version, “Er overgangsalderen en 
mangelsykdom?” [Is menopause a defiency disorder?]109.
In the 1970s and onward, this and other phenomena led to a feminist critique of 
the therapy110. The Norwegian GP Kirsti Malterud raised a debate on the principle of 
giving medical treatment to a phenomenon which is basically a natural process of the 
body111. However, the feminist critique of the therapy gradually vanished, and was more 
or less absent in the second half of the 1990s.
During these years, more positive attitudes towards hormone therapy (HT) during
and after the menopause were seen among doctors, in particular gynecologists, but also 
among GPs112. The most important reason was epidemiological evidence reporting that 
HT had positive preventive effect on several chronic health problems: osteoporosis, lower 
urinary tract infection, urinary incontinence and cardiovascular disease113-118, besides the 
positive effect on the menopausal symptoms. The prospects for the future of HT were
light: “Fortunately for humanity and the health care of women, knowledge about the 
hormonal defiency aspects of menopause has increased strongly in the last three 
decades.”119 (Editorial: 25 years of hormonal replacement therapy, Maturitas 1990).
Other benefits of using HT were many, more or less documented: enhancing sex life, 
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increasing libido, preventing aging of the skin, preventing dementia and loss of cognitive 
function – the most enthusiastic promoters virtually argued that use of HT preserved 
feminity and prevented aging. The literature regarding many of these effects are very 
sparse, and among clinicians presumed effects based on biological explanations, case 
histories and more anecdotic evidence was circulating. Most female gynecologists in this 
age used HT themselves112. The previous criticism of HT use as a medicalisation of a 
biologically natural phase of women’s life was more or less absent. It was therefore – in 
the medical community – a dramatic and more or less paradigmatic change that took 
place in 2002, when the first report from the large, randomized controlled Women’s 
Health Initiative (WHI) study was published20. The WHI study showed that HT use led to 
a slight increase of risk for cardiovascular disease, contrary to the common belief, and 
also to an increase in breast cancer and thrombosis. Before that, the HERS I study 
(1998)120 did not find the postulated preventive effect of HT on CVD, and this had 
already led to some cautions not to prescribe HT in order to prevent CVD. Later, the 
findings were confirmed in other studies, like HERS II121, and the oestrogen arm of 
WHI122. Large-scale observational studies published in the same period substantiated the 
magnitude of the increased breast cancer risk with different regimens and treatment 
duration, like the British Million Women Study (MWS)123 and the Women and Cancer 
Study from Tromsø, Norway124. Also, a Danish observational study published in the 
same period failed to prove a preventive effect of HT on death and ischemic heart 
disease125. The same researchers found that early menopause was a risk factor for CVD, 
but that HT did not have a protective effect in these women126. A Cochrane meta-analysis 
from 2005 summarizing the association between HT and stroke in 28 RCT’s (39 769
subjects) concluded that HT was associated with an increased risk of ischemic stroke 127.
Among subjects who had a stroke, those who took HT seemed to have worse outcome.
Following these results, most national and international guidelines for HT have been 
changed128,129. The purchased volume (DDD) in Norway has been more than halved since 
the top years of 1999-2000130.
Important research based knowledge before 2000 was under-communicated and 
did not get the necessary attention. Several observational studies had reported an 
increasing risk for breast cancer following long term use of HT among healthy women,
and a meta-analysis from 1997 summarized this131. For many doctors, the information 
regarding breast cancer risk was somewhat confusing, since several studies did not find
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an increased risk for relapse of breast cancer following HT,  and there are still 
controversies on the issue of oestrogen treatment following breast cancer surgery132.
After these publications, the HT of menopause has been more or less reduced to a 
treatment of bothering symptoms, and the search for alternatives has started. It can 
definitely be argued that Illich (and Malterud) was right: It is quite possible to cause more 
harm than good when the medical profession takes over and prescribe treatment. David L. 
Sackett characterized HT in an editorial in Canadian Medical Journal entitled “The 
arrogance of preventive medicine”133. He argued that the epidemiological evidence used 
for advocating HT as a preventive drug in the 1980s and onward was incomplete and 
partly erroneous, and that this was not understood and not taken care of by the profession: 
“I place the blame directly on the medical “experts” who, to gain private profit (from 
their industry affiliations), to satisfy a narcissistic need for public acclaim or in a 
misguided attempt to do good, advocate “preventive” maneuvers that have never been 
validated in rigorous randomized trials.”
The story of HRT (which is now HT) is an outstanding example of medicalisation,
of lack of evidence and lack of critical appraisal of the evidence which actually was there,
and an important lesson to learn for the most involved disciplines: gynecology and 
preventive medicine, and also general practice, since we deal with both arenas134. It 
shows us the fallacies of epidemiology, but also – at the same time – the wonderful 
benefits of science, in the context of a well designed, randomly selected and controlled 
intervention trial. 
But then: the doctors are left with their patients. Menopausal women continue to 
seek help for bothersome symptoms and concerns about their health and the various 
problems connected to menopause and aging. 
Use of HT – International and national recommendations
Following the publications of the randomized trials (HERS I and II, and WHI) 
guidelines were changed both in USA and Europe134,135. In Norway, the Norwegian Drug 
Agency [Legemiddelverket] arranged an expert meeting in 2003 to discuss the results and 
give recommendations for practice128.  The statements from NDA were (summarized):
- HT should not be used to prevent cardiovascular disease.
- HT is associated with an increased risk for breast cancer and the risk increase with 
the duration of treatment.
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- The risk for venous thrombosis and stroke is increased.
- The risk/benefit ratio has been changed towards greater risk and reduced benefit
with HT, and practice should be more restrictive. Every woman should be 
carefully advised with respect to benefits and risks with the treatment. 
- HT is effective against hot flushes. The lowest possible dose should be used, and 
the treatment should be revised annually. After 3-5 years a more rigorous 
evaluation should be performed, and discontinuation should be tested to assess the 
need.
- Vaginal discomfort due to hormonal changes (dyspareunia, small bleedings, and 
discharge) should be treated with local applications of estrogen. HT should not be 
used for bleeding disturbances or urinary incontinence. 
- Osteoporosis can be treated or prevented with HT, but other strategies should be 
used before HT.
The U.S. Preventive Task Force have recently (2013) issued a statement regarding 
menopausal hormone therapy for the primary prevention of chronic conditions136. This is 
an update of the 2005 statement, and is based upon a review of the literature about the 
benefits and harms of using HT for prevention of chronic disorders. The conclusion is a 
recommendation against the use of combined estrogen and progestogen for prevention of 
chronic conditions in postmenopausal women, and also against the use of estrogen alone 
among postmenopausal women who have had a hysterectomy.
The recommendation does not apply to the use of HT for treatment of vasomotor 
symptoms among menopausal women, and not for women below 50 who have had 
surgical menopause.
The North American Menopause Society have recently issued an updated position 
statement134. The need for individualized treatment is underscored, in contrast to the
recommendations of the 1990s. The decision to use HT should incorporate women’s 
health and quality of life priorities, and assess personal risk factors such as risk for venous 
thrombosis, breast cancer, stroke and CHD. HT should not be used for prevention of 
CHD or dementia, the society further states. 
The American Academy of Family Physicians (AAFP) also recommends against
the use of HT for prevention of chronic diseases among women. In Europe, the College of 
GPs in Holland has issued detailed recommendations which are even more restrictive 
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against HT, recommending treatment cessation after the shortest possible time (6-12
months)137.
Oral HT is highly effective in reducing vasomotor symptoms. The effect of HT to 
reduce the frequency and burden of hot flushes is demonstrated in a number of studies, 
and in a Cochrane Review from 2004 the reduction in weekly HF frequency compared to 
placebo was estimated to 75 % (64.3-82.3)138. Noteworthy, in women who were 
randomized to placebo, a 57 % reduction in HF was observed between baseline and end 
of study. 
Risk of HT – current evidence and controversies. The timing hypothesis.
The WHI study is by far the most extensive clinical trial of the effects and risk of 
HT. In the WHI study, 16 608 women aged 50 – 79 years were randomized to conjugated
equine estrogens plus medroxyprogesterone acetate, or placebo20. In the estrogen only 
study, 10 739 post-hysterectomy women of the same age were randomized to conjugated 
equine estrogen alone, or placebo122. The first study was stopped early because of 
increased risks for breast cancer, coronary heart disease, stroke and pulmonary embolism, 
and the estrogen alone study was stopped because an increased risk of stroke was found.
The results are summarized in Table 3. In later publications from WHI which included 
intervention and post-intervention phases (up to 8.6 years), the risk for CHD in the 
combined estrogen – progesterone study persisted (HR 1.22, CI 0.99 – 1.50)139 and in the 
estrogen alone no effect was shown (HR 0.95, CI 0.82 – 1.11)140.
In the debate after WHI, arguments against the findings have been that many 
women were older than those usually treated in Norway. Subgroup analysis from WHI 
has revealed potential lower incidence of CHD in the younger age group treated with HT
(50-59 years, HR 0.59, CI 0.38 - 0.90) but not in the older age groups (60-69 years and 
70-79 years)140. The P values for interaction by age were 0.05 and 0.007 respectively for 
CHD and myocardial infarction in the estrogen only arm, and were also apparent but less
pronounced in the estrogen + progestogen arm. These findings have led to the launching 
of a “timing hypothesis”: If HT is started early (close to the FMP, early postmenopausal), 
it may in fact have a cardio protective effect. A weakness with the hypothesis is that no 
prospective RCT has been designed to study the timing of initiation of HT. Recently, the 
publication of the Danish DOPS study (Danish Osteoporosis Prevention Study) has led to 
a new outburst of the HT debate141-143. The Danish researchers found that HT given to 
postmenopausal women during the first years after FMP reduced the risk for a combined 
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end point of death, myocardial infarction and heart failure, and did not increase breast 
cancer risk or stroke among women who used it for more than 10 years. From 1990 to 
1993, 1006 women aged 45 to 58 years, with last menstruation 3-24 months before, were 
enrolled in DOPS and randomly assigned to HT or placebo. Women with an intact uterus 
got 2 mg of 17-ȕ-estradiol 12 days per month and combination with norethisterone 
acetate 1 mg 10 days followed by 1 mg of 17-ȕ-estradiol in 6 days per month. 
Hysterectomized women received 2 mg of 17-ȕ-estradiol daily. The study was planned 
for 20 years, but after 10 years the investigators advised women on HT to discontinue 
treatment due to the WHI study results. At 10 years, HT had reduced the risk for the 
combined CVD end point (HR 0.48, CI 0.26 – 0.87) compared with no treatment. Also, 
there were no statistically significant increased risk for breast cancer (HR 0.58, CI 0.27 –
1.27), hospitalization for venous thrombosis (HR 2.01, CI 0.18 – 22.16) or stroke (HR 
0.77, CI 0.35 – 1.70). The results after the subsequent 6 years were similar. 
The DOPS and the follow up results from WHI lend arguments to the timing 
hypothesis. An argument against is that DOPS was designed to study the prevention of 
osteoporosis, and CVD or breast cancer incidence was not the primary end points. The 
composite end point was a combination of death and hospitalization for myocardial 
infarction and heart failure, and was based on registration by clinicians in the Danish 
Hospitalization Register. Since there are few numbers for each end point, the CI’s are 
wide and few missing numbers in the registers may cause different results. Also, since 
DOPS was an open-label study, the doctors and the participants knew if they were taking 
HT or not. This may lead to different use of health service and different advice on life 
style, other treatment and diagnostic efforts done by doctors and patients, in favor of a 
positive outcome.
The use of a composite end point is problematic, and may lead to exaggeration of 
positive outcomes144. This composite end point is not described in the original protocol, 
and the authors of the latest update of the Cochrane report on long term HT did not 
include the DOPS study145. The DOPS researchers argue that the end point is mortality-
driven, i.e. that CVD deaths are captured even though “softer” end points like angina or 
PCI may not be captured. Since the study participants are young, the number of deaths is
few and this may imply bias in the favor of fewer CVD events.
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A conclusion may be that the DOPS results support the timing hypothesis. 
However, the study is not sufficient to alter the recommendation that HT should not be 
used to prevent chronic diseases among post-menopausal women. 
 
Table 3. Results from the WHI study, estrogen + progestogen arm, 16 608 women aged 
50-79 at enrollment. Intervention group 8506 women, control group 8101 women. 
Primary end point: Events of CHD (not fatal myocardial infarction + any CHD death). 
Negative end point: Invasive breast cancer. Secondary end points: stroke, pulmonary 
embolism, uterine cancer, colorectal cancer, hip fracture, death of other causes. Mean 
follow up: 5.4 years. The study was stopped May 31st 2002 because of increased risk for 
breast cancer. Figures are calculations based on the published results. 
 
End point HR (95% CI) 
Intervention group Control group Events / 
10 000 
person 
year 
NNH, 
per year
Number 
of 
events 
AR per  
10 
years 
Number 
of events 
AR 
per 10 
years 
CHD  1.29 (1.02, 1.63) 164 3,74 122 2,90 8(1, 16) 1 189 
Invasive breast 
cancer 1.25 (1.07, 1.46) 166 3,54 124 2,83 7 (2, 12) 1 411 
Stroke 1.41 (1.07, 1.85) 127 2,74 85 1,94 8(17, -1) 1 255 
Colorectal cancer 0.63 (0.43, 0.92) 45 0,96 67 1,53 -6(-1, -9) -1 765 
Uterine cancer 0.83 (0.47, 1.4) 22 0,47 25 0,57 -1(3, -3) -10 293
Hip fractures 0.60 (0.45, 0.98) 44 0,85 62 1,42 -5 (0, -8) -1 764 
Death – other 
causes 0.92 (0.74, 1.1) 165 3,49 166 3,79 -3 (5, -10) -3 294 
Total death 0.98 (0.82, 1.1) 231 4,88 218 4,98 -1(9, -9) -10 033
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Table 4. Event rates, relative risk reduction and NNT in the DOPS study.146 Reprinted 
from the journal.
Hormone replacement therapy (HRT) vs. no HRT in recently postmenopausal 
women†
Outcomes Event rates After 10 y of therapy
HRT No HRT RRR (95 % CI) NNT (CI)
Death, MI, or HF‡ 3.2 % 6.5 % 50 % (11 to 72) 31 (22 to 144)
At 16 y
Death, MI, or HF§ 6.6 % 11 % 37 % (4 to 59) 26 (17 to 251)
†HF = heart failure; MI = myocardial infarction; other abbreviations defined in Glossary. RRR, NNT, and 
CI calculated from event rates and hazard ratios in article. Hazard ratio for the composite outcome was adjusted for 
age.
‡Death (3.0% vs. 5.2%, P = 0.08), MI (0.2% vs. 0.8%, P = 0.21), HF (0.2% vs. 1.4%, P = 0.07).
§Death (5.4% vs. 7.9%, P = 0.10), MI (1.0% vs. 2.2%, P = 0.14), HF (0.6% vs. 1.6%, P = 0.15).
Discussing the treatment options: The GP as advisor.
The risks and benefits of HT use is a challenge for the doctor who is supposed to 
give women information and for the women to take the decision to use it or not. The role 
of the GP when giving advice and prescribe treatment is a part of the thesis and is 
explored in the GP survey. 
During the last 3 decades, the knowledge about decision making in medicine and 
questions regarding treatment options and informed choices for patients have undergone 
great changes. The doctor’s role has changed from a paternalistic teacher to a source of 
information for patients who ideally take their own informed decisions, with many grey
zones in the intermediate space. The patients’ rights are reflected both in the legislation 
and in ethical considerations.
The ideas of patient centered medicine and patient empowerment are central in 
modern medicine, and have been studied in general practice settings147,148. McWhinney 
describes the patient-centered approach as one where “the physician tries to enter the 
patient’s world, to see the illness through the patient’s eyes”149. Patient centered 
medicine can be described as the process where the doctor actively explores the patient’s 
perspective: the needs, fears, feelings and wishes expressed by the patient in the 
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consultation. The doctor integrates this knowledge with her own medical knowledge and 
skills, and discusses the further investigation and possible interventions with the patient.
During this process, the patient is empowered to take his or her own informed choice 
when deciding about a treatment. The aim of the consultation is a shared understanding 
of the patient’s problems. A comprehensive framework of the notion of patient-centered 
medicine is given by Stewart et al, identifying the crucial components of the method150.
Shared decision making – or informed choice?
Ideally, shared decision making means that the patient and the doctor discuss the 
options (e.g. prescription or not) on a basis of mutual respect and equality, and the final 
decision is a consensus151. Shared decision making raises many problems. If the doctor 
does not agree to the women’s decision, prescription or not may collide with her
professional responsibility. On the other hand – an insisting doctor may override the 
personal preferences of the patient and which may imply a violation, thereby causing
damage to the patient-doctor relationship. When it comes to HT, some data has indicated 
that the women maintain that they take the decision themselves, but that the doctors are 
important information sources152. Some authors have used the notion of compliance 
here153, which indicates a more paternalistic view of the process. When a prescription has
been given to a woman, the woman’s decision of not buying the medicine (or not taking 
it) has been regarded as an example of non-compliance. Other perspectives for the 
discussion between the doctor and the concerned woman have been advocated, taking 
into account the risk for medicalisation and disease-making of a natural process154. It is 
reason to believe that the nature of the decision process has changed after the WHI 
results, since the risks of HT has been described and quantified, and the risk-benefit 
balance has tipped against HT use.  In a dissertation from Sweden, Hoffmann has 
discussed the framework and the process of communication about risks and benefits of 
HT155. When analyzing consultations in 5 gynecological practices in a qualitative research 
design, he found that discussion about risk was asymmetrical, with the physician 
dominating in a 4:1 ratio of spoken words. HT was introduced by the doctor in 19 out of
20 cases, and in 15 of these in a positive mood. The patient’s participation in the decision 
making process was modest, in 13 cases the women’s preferences were explored, but in 
only 2 of the cases the woman’s role in decision making was addressed. Quantification of 
risk was used in 5 of the 20 consultations, where absolute risk rates for breast cancer were
used. The doctors used different rhetorical strategies in the consultations, including
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renaming of the words (drawbacks instead of risks), simplifying calculations, framing of 
HT in a positive way etc156. A possible conclusion from these findings is that the notion 
of patient-centered medicine had little impact in these gynecological practices.
Using HT (or not) should be a question of informed decision making by the 
woman herself, based on information from many sources: The doctor (GP and/or 
gynecologist), friends, husband, media, alternative channels. The challenge for the doctor 
is to give the woman scientific based, precise and relevant information about the benefits 
and risks of HT use, based on recommendations and guidelines and taking into account 
the patients “ideas, fears, wishes and needs”. In some circumstances, the doctor may feel
that a prescription is contra-indicated, and in others she may feel that the woman will 
have more to gain than to lose. 
How do doctors decide?
Traditionally, the decision framework in medicine has two main roots: biomedical 
science and “humanistic tradition/philosophy”. Several underlying components are 
derived from this framework157. Often, the road to a decision is visualized by means of a 
decision tree. In the clinical situation, however, doctors seldom use these algorithms. 
There may be several reasons for this: using algorithms and decision tools are time-
consuming, and do not exactly cover the situation in case. Experiments and research from 
other disciplines (psychology, economy) has led to new insight in decision making, which 
may be applicable for how to understand clinicians. 
The term heuristics denotes mental shortcuts, often used in complicated questions 
when a quick decision must be taken158. Different ways to interpret risks (side effects) are 
also important in this respect, and will be further discussed below.
How do doctors interpret probabilities and risk?
Often, risk or risk reduction is communicated by means of differences between a 
treatment group and a control group – the relative risk reduction. As an example: 
treatment with a statin reduces the risk for CHD by 30 %, compared to a group not 
receiving this treatment. The statement is easy to understand, and sells well.
But this information gives us no idea regarding how big the risk (and the risk 
reduction) is: What is the absolute risk reduction for my patient? For how long time 
should he or her be treated? And what are the side effects? What is the “real benefit” for 
my patient? We obviously need more information. When we talk about HT, there are 
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benefits and risks, and we must assume that both doctors and patients calculate them 
differently.
In Table 3, a more detailed presentation of the WHI results are given. These 
results can be interpreted in different ways:
1. Relative risk: Treatment with HT increases the risk of coronary heart disease with 
29 %.
2. Absolute risk: The mean 10 year risk for coronary heart disease increase with 0.8 
% - from 2.9 % to 3.7 %.
3. Absolute risk: When treating 1000 women in 10 year, 8 more will get CHD (with 
95% probability: at least one, at most 16).
4. Absolute risk, number needed to harm: If 1200 women is treated with HT in one 
year, one more will get CHD. 
Based on the MWS results, the authors calculated 20,000 additional cases of 
invasive breast cancer in Great Britain during the 10 year period 1990-2000123. In a 
Norwegian setting, the number has been calculated up to 150 – 250 additional cases per 
year 124, which is even greater burden than what was found in GB. 
For patients, and even doctors, it is difficult to interpret these results. What do 
they actually mean? Is the risk difference big or small for the individual women? It 
becomes even more demanding when more complicated calculations come up. How many 
life years without disease will I loose? 3 months? 3 years? The answer will depend on
other risk factors and other treatment, and we know little about how doctors and patients 
deal with these calculations.
Because the knowledge of risks and benefits has been changed and the scientific 
evidence is diverging and partly unknown, the perceptions of the magnitude of risk 
among both the doctors and the women probably are diverging. There is a need to explore
how the doctors interpret the evidence, their role as information and discussion partners 
and how they will advise their patients. This was a theme for the GP study. At the same 
time, both the women and the doctors need updated and reliable information regarding the 
usual menopausal symptoms, how they relate to age and menopausal status, the duration 
of symptoms and factors associated with burden of symptoms. These are among the 
questions elucidated in the HWC study.
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Research questions. 
Overall research questions: 
1. What are the attitudes and knowledge of HT among Norwegian GPs after the 
changing of the evidence?
2. What is the symptom burden and use of HT during the menopausal transition 
among healthy Norwegian women?
GP study 
In the papers, research question 1 has been further developed into:
1. What are GPs’ views regarding effects, indications, contraindications, risks and 
duration of HT treatment, and are these views in line with the Norwegian 
recommendations? (Paper I)
2. Do the GPs regard that use of HT imply medicalisation of the menopause? (Paper 
I)
3. Are there differences between the GPs regarding views and attitudes to HT, and if 
so - which factors are associated with these differences? (Paper I)
4. Do female GPs use HT themselves, or (for younger GPs) do they consider to use 
HT? (Paper I)
5. What is the GPs’ perception of role when giving advice regarding HT? (Paper II)
6. Do GPs give different advice to women regarding HT, and if so - does perception 
of effects and risk of HT, attitude to treatment or other factors influence the advice 
given? (Paper II)
HWC study: 
In the papers, research question 2 has been further developed into:
1. What are the symptom prevalences and symptom burden over time during the 
natural menopausal transition? (Paper III)
2. Are health factors, life style or sociodemographic factors associated with degree of 
symptoms? (Paper III)
3. Are the symptoms associated with self-rated health? (Paper III) 
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4. What is estimated age at menopause? Are there possible factors associated with 
this age? (Paper III)
5. How is the characteristics of HT use among healthy Norwegian women during the
menopausal transition, and which factors are associated with HT use? (Paper IV)
6. Do the vasomotor symptoms reappear after discontinuation of HT? (Paper IV)
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Material 
This thesis is based on two sets of data:
1. The GP study: a cross-sectional survey conducted in 2004 among 400 Norwegian 
GPs, randomly selected from the Norwegian Medical Association’s list of GPs
with contract with the municipalities. The results of this study were originally
published in two Norwegian papers, later translated to English and available at the 
Journal’s web site (Paper I and II).
2. The HWC study: The Hordaland Women’s Cohort study - a longitudinal cohort 
study from western Norway. The Cohort was established in 1999, and has 
baseline data from Hordaland County Health Survey (HUSK) 1997-98. The 
Cohort consisted of 2229 women aged 40-44 at baseline, and the women have 
received almost identical questionnaires approximately every second year. The 
material is based on seven questionnaires (1999 - 2010). The first paper regarding 
menopausal symptoms (Paper III) has been published in Maturitas. The second
paper from the cohort (Paper IV) has been submitted and follows as an 
attachment.
The GP Study. 
In 2001, a reform took place in the Norwegian Health system, when a list system for 
General Practitioners (The Regular GP Scheme) was formed. Every Norwegian citizen 
was given the right to join the list of a GP. The system is run by the local authorities 
(municipalities), and almost every GP and 99.5 % of the population joined the system159.
In 2004, the Norwegian Medical Association kept a list of approximately 3600 doctors
who were registered as Regular GPs in the membership database. The number of GPs in 
the NMA register was a little less than the number in the Norwegian Health Directorate 
database160 (3600 vs. 3755), since not all GPs are members of NMA. 400 GPs
(approximately 11 % of the GPs) were randomly drawn from the NMA database to form 
the GP panel in the survey.
After reminders, 289 responders (72.3 %) were included for analysis. 29.8 % of the 
respondents were women, the same as in the Norwegian Health Directorate database. The 
mean age of all respondents was 45.4 years (range 26–69 years), two years younger than 
the mean in the total GP population.  The distribution of patients on the lists could not be 
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compared directly, since the response alternatives in the questionnaire was a grouping of 
the list length. The average number of years in practice was 14 years (range 1–37 years). 
Recorded characteristics of the responders are shown in Table 5.
Table 5. Characteristics of the GP sample 2004 and the GPs in Norway. Proportion of 
female GPs, mean age (with 95 % CI), age distribution, number of patients on list, years 
in practice and practice region (part of the country).
GP Sample 2004 GPs in Norway 2004*
N % %
Number 289 3755
Proportion female (%) 86 29.8 29.9
Mean age (years)** 287 45.4 (44.4 - 46.4) 46.6
Mean age male GPs 202 46.9 (45.7 - 48.0) 48.3
Mean age female GPs 42.0 (40.4 - 43.6) 42.9
< 30 year 5 1.7 1.4
30-39 year 69 23.9 20.8
40-54 year 174 60.2 54.0
55-66 year 38 13.1 22.7
67 year 1 .3 1.1
No of patients on list
< 500 9 3.1
Mean number
1199
501-1000 63 21.8
1001-1500 154 53.3
> 1501 57 19.7
Years in practice (mean) 14 -
Practice region**
Eastern Norway 131 46.0 49.6
Southern Norway 17 6.0 6.4
West Norway 76 26.7 24.6
Mid Norway (Trøndelag) 24 8.4 8.6
North Norway 37 13.0 10.7
*Figures from Norwegian Health Directorate, statistics 2001 – 2011, downloaded Jan 13, 2013.
**Mean age and Practice region (part of the country) was reported from NMA database.
The Hordaland Women’s Cohort (HWC)
The Hordaland County Health Survey (HUSK)161 was a joint epidemiological 
research project carried out by the National Health Screening System of Norway (now:  
Norwegian Institute of Public Health) and the University of Bergen. It is a part of the 
national database for epidemiological research in Norway – the Cohort of Norway 
(CONOR)162. The CONOR questions cover the following main topics: self-reported
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health and diseases such as diabetes, asthma, coronary heart disease, stroke and mental 
distress, musculoskeletal pains, family history of disease, risk factors and lifestyle, 
surrounding environment, social network and social support, education, work and 
housing, some occupations, use of medications and reproductive history (women). Most 
of the studies consist of a central core and several supplementary projects.
HUSK is a county based health survey in Hordaland County in Western Norway, 
and include the city of Bergen which is Norway’s second biggest city. HUSK consists of 
a baseline registration obtained in 1997-1999, including all inhabitants in the county of 
Hordaland born 1953-57, then in ages 40-44 years (29,335). A total of 18,851 (63 %) 
invited persons met at the screening stations. Baseline measurements from HUSK 
included body height and weight, and blood pressure. A non-fasting blood sample was 
also collected. The self-administrated baseline questionnaires in HUSK included open-
ended questions on occupation, income, use of medicines, various health behaviors, and 
some self-reported diseases (among others diabetes, cardiovascular disease, 
asthma/allergy).
Forming of Hordaland Women’s Cohort (HWC). 
Women who came to the screening station in HUSK received information about 
the Cohort. They eventually agreed to take part in the HWC by signing an informed 
consent form. For random sampling, the last digit of the personal ID number was used. 
For the necessary sample size a preliminary power calculation, based on a 70% response 
rate at inclusion and 5% annual attrition rates was used. With this calculation, at least 
2,150 women should be asked to join at the baseline if at least 900 women should remain 
in the cohort after 10 years.
From the female participants in the HUSK study (N=14,349), a random sample of 
3,453 was invited to participate in the Hordaland Women’s Cohort (HWC) study, and 
2,331 (67.5%) of them met. After oral and written information, 2,230 (95.7%) women 
aged 40-44 years at the date of inclusion consented to take part in the study. One woman 
died before the first questionnaire was registered, so the final number in the Cohort was
2,229. A written consent form, including declaration of willingness to participate in 
follow-up questionnaires at regular intervals during the next 15 years, was signed by the 
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participants. More details regarding the recruitment and the Cohort participants are 
described elsewhere163.
The baseline characteristics of HWC are summarized in Table 6. There were no 
significant differences between the Cohort and the rest of the female participants in 
HUSK, except for education and annual family income, which were slightly higher 
among females in the Cohort163.
Fig.2. Forming of the Hordaland Women’s Cohort (HWC). Baseline registration in the 
HUSK study, sampling and recruitment procedure.
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Table 6. Comparison of baseline socio-demographic characteristics between the HWC and the 
rest of the women in the Hordaland Health Study (HUSK).163
HUSK minus 
the Cohort 
(N = 7746)
The Cohort 
(N = 2230) P values
N % N %
Age at inclusion (years)
40 1465 18.9 481 21.6
41 1518 19.6 478 21.8
42 1578 20.4 456 20.4
43 1521 19.6 500 22.4
44 1664 21.5 315 14.1
Marital status 0.88
Not married 788 10.2 230 10.3
Married 5800 74.9 1676 75.2
Single 82 1.1 23 1.0
Divorced 861 2.7 248 2.4
Separated 212 2.7 53 2.4
Registered partnerships 3 0.03 0 0
Education 0.001
Elementary school 1616 20.7 408 18.2
The lower secondary 2687 34.7 749 33.6
The upper secondary 755 9.8 284 12.7
University less than 4 years 1371 17.7 410 18.4
University 4 years and more 1211 15.6 365 16.4
Missing 106 1.4 14 0.6
Annual family income, NOK 1000 0.018
0-199 1103 14.2 271 12.2
200-399 2483 32.1 702 31.5
> 400 2810 36.3 924 41.4
Missing 1350 17.4 333 14.9
Parity 0.768
0 544 7.0 166 7.4
1 731 9.4 211 9.5
2 2596 33.5 803 36.0
3+ 2802 36.1 794 35.6
Missing 1073 13.9 265 11.9
Body mass index (kg/m2) 0.328
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Under-weight (< 18.5) 96 1.2 27 1.2
Normal (18.5-24.9) 4582 59.2 1357 60.9
Overweight (25-29.9) 2247 29.0 628 28.2
Obesity 797 10.4 216 9.6
Missing 24 0.3 2 0.1
Self-rated health 0.170
Bad 91 1.2 18 0.8
Not very good 1120 14.5 294 13.2
Good 4791 61.7 1407 63.1
Very good 1665 21.5 497 22.3
Missing 79 1.0 14 0.6
Lifestyle and medical conditions 0.199
Regular exercise 4519 58.4 1342 60.2 0.199
Daily smoking 2727 35.2 757 33.9 0.482
Asthma 503 6.5 155 7.0 0.444
Diabetes 87 1.1 23 1.0 0.715
Alcohol intake > 6 times/month 1417 18.3 418 18.8 0.095
Psychiatric problem/condition 1144 14.8 314 14.1 0.229
Reprinted from Jahanlu D, Qureshi S A, Hunskaar S.: The Hordaland Women's Cohort: a prospective 
cohort study of incontinence, other urinary tract symptoms and related health issues in middle-aged women.
Study Protocol.  BMC Public Health 2008, 8:296.
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Methods  
Study design
The GP study was a cross-sectional observational study based on a random sample 
of Norwegian GPs.
The Hordaland Women’s Cohort is a longitudinal cohort study, based on a 
randomly selected, representative group of women and followed with questionnaires
approximately every second year. The cohort will be followed for 15 years. The material 
included in the papers contains data collected at baseline (from the HUSK study) and the 
first seven waves up to 2010. The eighth wave was performed in 2012.
Questionnaires
GP Study 
A questionnaire with a total of six background variables and 17 main questions 
was used in the survey, and is attached (in Norwegian) as Appendix A.
The questionnaire was developed by the author (B.G), in collaboration with the co-
authors of Paper I, and included questions about the role of the doctor when giving 
advice, the knowledge about and adherence to guidelines, assumed effects of HT, 
indications and contraindications, conceptions about risks and attitudes to HT
prescription. 3 clinical examples (cases) concluded the questionnaire. Some of the 
questions regarding indications and contraindications had been used previously in a 
survey of Norwegian gynaecologists112.
Since the prevalence of consultations regarding HT could influence knowledge 
and attitudes, we asked the GP to indicate how often HT was a theme: How often do you 
discuss HT with patients? The response alternatives were: Less than once per month, 1-4
times per month, 1-3 times per week, or almost every day. Also, the changing of the 
evidence base could have led to confusion or difficulties when giving advice among the 
doctors. The question Do you experience that it is difficult to give advice (to consider 
benefits and risks) regarding HT? intended to explore this theme. The response 
alternatives for the question were divided in five categories: No, never – Seldom –
Occasionally – Often – Yes, always. Question about the role of the physician was To 
which extent do you as doctor or the patient take the initiative to start (and in the next 
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question: to stop) HT? The response alternatives were also for this question divided in 5 
categories: Almost always me as doctor - Most often me as doctor - Equally often the 
patient as the doctor - Most often the patient - Almost always the patient. The same 
question was also applied to the task of stopping treatment, with the same response 
alternatives. 
The adherence to recommendations regarding revision of treatment and treatment 
duration was asked for with the question Do you have a main rule for duration of HT 
when treating menopausal symptoms? The response alternatives were yes or no, and if 
yes: for how long time: shorter than one year - one up to three years  - three to five 
years - more than five years.
A group of questions explored the attitudes to statements regarding effects of HT, 
indications and contraindications: What is your opinion regarding the following 
statements? Response alternatives mostly agree - somewhat agree - neither agree nor 
disagree - somewhat disagree - mostly disagree. The statements are described in more 
details in the Dependent variables paragraph. The purpose of these questions was to 
explore to which extent other factors than the burden of vasomotor symptoms was 
significant as possible reasons to prescribe HT. e.g. preventive effects or more speculative 
effects on sex life, aging of the skin, or making women more attractive and counteract 
signs of ageing. Although the medicalisation debate regarding HT had taken place some 
years ago in Norway, we also suggested that the attitude to this question was relevant for 
some of the doctors. The attitudes were explored with the statement:  HT implies an 
undesirable medicalisation of a natural life phase in women. The response alternatives 
were the same as indicated for the other statements.
To explore the attitudes to the risks of HT and possible influence on attitudes to 
prescription, we also asked the following questions: In your everyday practice: Do you 
feel that it is important to know how high the risk for side effects of HT is? Following this, 
three different ways of displaying the risk estimates were given, and the doctors were 
asked which one they preferred: 
- When using HT in five years, the risk for breast cancer increases with 
approximately 30 %.
- The absolute risk for breast cancer after five years of HT increase from 
approximately 0.25 % per year to 0.31 % per year.
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- When 1000 women are treated with HT in 10 years, 8 more women will get breast 
cancer.
Following the risk estimates, the doctors were asked to assign the significance of 
these risk estimates in the clinical situation: small/minimal, some or great significance,
and also tick for to which extent they have changed their practice: much more restrictive -
somewhat more - about the same - somewhat more - much more liberal.
Finally, three clinical examples were given. The purpose was to illustrate the 
options (prescription or not) by cases recognizable in a general practitioner’s everyday 
situation, in order to study possible factors associated with a positive or negative attitude 
to treatment. The cases were meant to illustrate different clinical situations, and are given 
in the Dependent variables section. The first was a woman without obvious indications 
for treatment (bothersome vasomotor symptoms), the second an older women where long 
term treatment should not be recommended, and the third a situation when other options 
(prescription of gestagen only) probably was the best choice. Four options were given, 
supplemented by a commentary field for personal responses:
Tick for the advice you will give to the patient:
- I will recommend HT
- I will neither recommend nor advise against HT
- I will not recommend HT
- I will strongly advise against HT.
For the last case, the options yes - no - do not know were given. 
In the questionnaire, the last question was for female doctors only. The purpose 
was to explore the attitude to HS use by the female GP’s themselves. We also discussed 
to include a question to the male GP’s whether they would prescribe HT for their 
partners, but decided not to include it since it could be regarded mal practice to prescribe 
medication to partners. If before menopause: Would you consider using HT during the 
menopausal transition? The response alternatives were Yes - No - Do not know. For those 
in the transition or after menopause: Do you use HT? (yes – no- used earlier). If use or 
used before: What is the name of the medication? For how many years have you used 
HT? If used earlier: How many years did you use HT?
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Pilot study 
The questionnaire including the cases was tested on two different panels of GPs.
The first group consisted of eight experienced doctors in a CME group and the second 
group consisted of eight younger doctors in an education group for specialization in
General Practice. Thus, the pilot groups contained both young and inexperienced and 
older and more experienced GPs. In these group settings, the doctors knew each other and 
were experienced discussion partners. In both groups, the questions were discussed in 
detail to ensure a common understanding and interpretation of the statements and 
questions. The panels agreed that the questions and statements were relevant for GPs 
giving advice to women in the menopausal transition. The clinical examples were also 
presented on a larger CME course regarding women’s health arranged by NSAM in 
March 2004. The discussions following the presentation of the cases led to minor 
adjustments to ensure a common understanding. 
HWC Study questionnaire 
Since 1999, a two-paged questionnaire has been sent approximately every second 
year to the HWC-participants.  The questionnaires have been almost identical each time, 
and consist of 4 main parts. The questionnaire used in Wave 7 is printed in Appendix B
(Norwegian version).
The first part (health and lifestyle) contained questions regarding age, self-rated 
overall health, visits to doctor/hospital, weight, pelvic exercise, physical exercise and
smoking. This part also contained questions regarding complementary treatments such as 
acupuncture and homeopathy. In Wave 7, the women were asked to fill in the date for 
completing the questionnaire and their present age.
The second part (menstruation, menopausal symptoms and contraception) contained 
questions regarding menstrual pattern and last menstrual period, vasomotor and vaginal
symptoms, use of HT and contraception use. In Waves 1 and 4, the women were asked if 
they had the ovaries and/or the uterus removed. The wording of the questions regarding
menstruation and menopausal symptoms were formulated after discussions with the 
investigators who had performed the Norwegian Menopause Project (1985-1989), and are
shown in Box 1 below.
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Box 1. Questions regarding menstrual periods and menopausal symptoms in HWC.
The wording of questions regarding HT use was: Do you use hormones against 
menopausal complaints? Response alternatives in the different waves were:
- Wave 1: yes – no. In Wave 2, the question was omitted.
- Wave 3 – 6: yes – no – used before.
In Wave 7, I had the opportunity to formulate some additional questions in order 
to characterize HT use in more detail, and control for start and duration of HT use not 
captured by the original questions. Also, questions regarding discontinuation of HT were
included, since it had emerged as a research question at that time. The response 
alternatives regarding HT use were further developed into: yes – no, never used – used 
before; how long: ___year ___months. How old were you when you started HT? ___year.
Why did you stop HT? Response alternatives: I had side effects - I was worried about 
possible side effects - No longer needed - Other reasons:……. 
The third part contained questions about urinary conditions: voiding (bladder 
function) and incontinence which has not been used in this thesis.
The last part of the questionnaire contained questions about medication and/or 
complementary drugs used the day before. In the introduction to the question, “medicine” 
was explained as any drug with or without prescription, in any form. In a chart, the name 
of the medicine,  if it was a daily (regular) intake, and the reason to use it could be 
indicated. The data from this part has been analyzed for the HT users in Wave 7.
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Data collection
GP Study 
In May 2004, the questionnaire was sent to these 400 Norwegian GPs. Every 
questionnaire had a unique number on the answer envelope connected to the name and 
address of the GP, so it was possible to send out reminders.  The responses (answers) 
were processed anonymously. After a postal reminder in June, 204 responses (51 %) had 
been returned. In August, 108 non-responders were contacted by phone, and additional 
reminders were posted. In November 2004, 304 responders (76 %) were registered. 15 of 
these denied to participate or had stopped practice and was excluded from analysis. The 
remaining 289 responders (72.3 %) were included for analysis (Table 7).
Table 7. Survey among General Practitioners in Norway 2004. Number and % invited, 
questionnaires returned and included in analyses.
Sample N %
Invited 400 100
Questionnaires returned 304 76
Denied, stopped practice etc 15 3.7
Included in analyses 289 72.3
HWC Study 
The data collection in HUSK (1997-99) for the HWC-participants formed the 
baseline data in the Cohort. The first wave was performed in 1999 and the second wave 
in 2000. From year 2000, a questionnaire was sent to members of the HWC every second 
year. In order to maintain the lowest possible attrition rate in the Cohort, non-responders 
received up to three postal reminders. In 2010, the Cohort had completed seven 
questionnaires (waves) and the age range of the participants had reached 53-57 years 164.
The response rates in waves 1-6 varied between 87% and 93%. In Wave 7, the number of 
remaining participants in HWC was 2157 and the response rate was 82 %.
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Fig 3. Time flow in the cohort. The seven waves in HWC. Age span.
Preparation of the material
GP Study 
The returned questionnaires were processed anonymously into an SPSS 
worksheet. Written comments were collected in a separate file and checked manually by 
the author. 
HWC study 
Because our primary aim was to describe the menopausal transition, symptom 
distribution, and HT use in healthy women, we excluded data from 174 women who had 
undergone bilateral oopherectomy and/or hysterectomy. Also, members of the Cohort 
who had not answered questions regarding last menstrual period in any of the seven 
waves (n= 53) were excluded from analysis. The remaining responders (n=2002, 89.8 %) 
made up the dataset used in most of the analyses (Table 8). There were no significant 
differences with respect to baseline characteristics between the dataset analyzed and the 
Cohort as a whole (Table 9). The excluded individuals (n=227), however, were slightly 
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older, had lower income, were more obese and less physically active than those in the 
dataset analyzed.
Table 8. Samples in the HWC study.
N %
Cohort at baseline 2229 100
Oopher- and/or hysterectomized* 174 7.8
Missing menstrual data in all waves 53 2.4
Dataset 1,  used in most analyses 2002 89.8
Hormone IUD users, Wave 1 274 12.3
Dataset 2 (hormone IUD users W 1 excluded)** 1728 77.5
*According to responses given in Wave 1 and Wave 4.
** Used in analyses of factors associated with Age at FMP, Paper III.
Table 8b. Missing values in the sample (Dataset 1).
Wave no 1 2 3 4 5 6 7
Menstrual data missing (%) 7.4 18.5 7.6 12.1 14.1 16.6 23.9
Use of HT missing (%) 13.3 -* 9.5 13.8 15.9 17.2 21.4
Frequency of hot flushes missing 14.1 24.1 11.7 14.2 17.6 18.4 22.7
*In wave 2, this question was omitted.
The use of gestagen containing hormonal intrauterine device (IUD) often leads to 
more sparsely bleeding or absence of normal menstrual bleeding. This may lead to 
uncertainty as to reporting of FMP. In the analysis of factors influencing FMP, 274 
hormone IUD users (reported in wave 1) were excluded. The remaining dataset (Dataset 
2) included 1728 respondents and were used to analyze factors associated with age at 
FMP (Table 8).
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Table 9. Baseline characteristics of women in the complete Cohort and the part of the 
Cohort left to analysis. Data at inclusion in HUSK 1997-99.
The complete Cohort 
(N=2229)
Respondents analyzed   
(N=2002)*
N % N %
Age at inclusion (years)
40 481 21.6 436 21.8
41 478 21.8 441 22.0
42 455 20.4 409 20.4
43 500 22.4 441 22.0
44 315 14.1 274 13.7
Self-rated health at inclusion
Bad 18 .8 18 .9
Not very good 294 13.3 250 12.6
Good 1406 63.5 1255 63.1
Very good 497 22.4 466 23.4
Lifestyle and medical conditions
Physically inactive# 863 38.7 756 38.0
Daily smoking 757 33.9 625 33.4
Asthma 155 7.0 142 7.2
Diabetes 23 1.0 20 1.0
Alcohol intake >6 times/m 234 11.0 212 11.1
Body Mass Index (kg/m2)
Under-weight (<18.5) 27 1.2 24 1.2
Normal (18.5-24.9) 1357 60.9 1231 61.6
Overweight (25-29.9) 628 28.2 559 28.0
Obesity (>30) 216 9.6 185 9.3
Parity
0 172 7.9 150 7.6
1 237 10.8 210 10.7
2 907 41.4 815 41.5
3+ 873 39.9 791 40.2
Marital status 
Married/partnership 1675 75.1 1506 75.3
Single/widow 253 11.4 230 11.5
Separated/divorced 301 13.5 265 13.2
Education
Elementary school 408 18.5 360 18.1
The lower secondary school 749 33.6 668 33.6
The upper secondary school 283 12.7 255 12.8
College, bachelor degree (< 4 
years)
410 18.4 368 18.5
University, master degree 
(=>4years)
365 16.4 338 17.0
Annual family income 1997  NOK 
1000
Low: 0-199 271 14.3 233 13.5
Middle: 200-399 702 37.0 640 37.0
High: >400 924 48.7 855 49.5
*Respondents not oopher- and/or hysterectomized, not missing menstruation data in the observation period. 
# < 1 hour hard activity (being warm, sweating) and/or < 3 hour light activity, per week, valid per cent.
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Because recorded data in the first six waves did not include an exact date for when the 
questionnaire was filled in, we allocated the month following the distribution of the 
questionnaire as the response month. This was adjusted according to the schedule for the 
postal reminders. Since up to three postal reminders were sent, the allocation of FMP in 
the cohort became complicated and time-consuming.
To study the associations between symptoms and age, the questionnaire responses 
were reorganized according to two-year age groups. Each woman will thus appear in 
seven groups, in which will depend on her age at baseline. Each age group had data from 
up to three different waves, and a woman could not deliver data more than once in each 
age group. The number of participants in the 41-42 years age group, the 43-44, the 55-56,
and the 57 year group, respectively, were 877, 1728, 1125 and 274. These figures are all
lower than the total of the dataset, 2002, since no women covered the whole age range 
during the study period.
Many cases had missing values for HT use in some of the waves (Table 8b). In 
Wave 7, 190 women completed their age when starting HT and the duration of use. Thus, 
valid values for HT use during previous waves were inferred for 177 cases based on these 
data. This inference resulted in fewer missing values for HT use in the different waves 
and 35 more women were categorized as HT users. In Wave 7, 16 additional women 
reported previous HT use for three months or less. These women were categorized as 
nonusers. Besides obtaining more accurate count of HT users, an important reason for the 
inference was to obtain fewer missing values in the case-control substudy, since missing 
values would reduce the number of cases in the analyses.
Dependent variables.
The dependent variables used in statistical analyses in the different papers are 
shown in table 10 below. In addition, a number of variables were reported only in 
descriptive statistics.
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Table 10. Dependent variables used in different papers.
Study Population N Dependent variables Paper numberI II III IV
GP 
study
Norwegian general 
practitioners
289 Statements of treatment 
effects, medicalisation
x
Assessment of indications 
and contraindications
x
Rule for treatment duration x
Assessment of role in 
prescription of HT
x
Advice, clinical examples x
HWC Women in 
Hordaland, born 
1953-57
2002 Frequency and burden of 
VMS and vaginal dryness
x
Age at menopause x
Self-rated health x x
Use of HT x
Short-term vs. long term HT 
use
x
Start of HT before vs. after 
FMP
x
GP Study 
Statements regarding effects of HT 
A group of questions explored the attitudes to statements regarding effects of HT: 
What is your opinion regarding the following statements? Response alternatives mostly 
agree - somewhat agree - neither agree nor disagree - somewhat disagree - mostly 
disagree. To analyse the perception of the effects and attitude to treatment, those who 
responded “mostly agree” and “somewhat agree” were combined and tested against the 
combined group that responded “somewhat disagree” and “mostly disagree”, with and 
without those who responded “neither agree nor disagree”. 
Hormone therapy: 
- Increases risk of breast cancer
- Prevents Alzheimer’s disease
- Delays skin aging
- Improves sex life
- Makes women more attractive
- Protects against cardiac infarction
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- Protects against colon cancer
- Increase life expectancy for women
- Implies an undesirable medicalisation of a natural life phase in women
Indications and contraindications 
A second group of questions explored the doctor’s attitude to indications and 
contraindications: How great emphasis would you place on these indications or counter-
indications to prescribe HT? The response alternatives were great emphasis - less 
emphasis - no emphasis - don’t know. In the analyses, the response alternatives were 
grouped in two alternatives: Those who put “great emphasis” vs. those who put “less” or 
“no emphasis” on the indication or contraindication. In the Methods section of Paper I,
the description given is by accident not correct. Here, it says that “great emphasis” and 
“less emphasis” were grouped together and tested against “no emphasis”. Both 
alternatives were tested, and the description given in the table (Table 4, Paper I) is 
correct. These dichotomised response categories were used and the associations for each 
indication or contraindication listed below were assessed by means of logistic regression:
- Hot flushes and/or sweats (disturbing)
- Genetic predisposition for osteoporosis
- Mood swings
- Discomfort due to dry mucous membranes
- Reduced libido
- Aging of the skin
- Breast cancer (previously, treatment completed)
- Breast cancer in first degree relatives
- Cardiovascular disease with symptoms
- Thromboembolic disease among close relatives
Rule for treatment duration 
The 2003 recommendations advised that treatment should be revised annually, and 
a more extensive evaluation and discontinuation attempts should be carried out after 3-5
years. We asked the doctors if they had a general rule for treatment duration, and if so –
how many years. The response alternatives were –less than one year, 1 up to 3 years, 3 up 
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to 5 years, 5 years or more. In the analyses, those who answered “yes” were compared to 
those who answered “no” to this question.
Clinical examples 
Three of the questions in the questionnaire were formulated as clinical examples
where doctors were requested to give an opinion about whether they would advise using
HT or not, and they could also give their own comments. Responses regarding Clinical 
examples 1 and 2 were used as dependent variables in the analyses:
Clinical example 1:
Woman, 55 years old, has not used HT previously. Last menstruation about 2 years ago. 
She has experienced some hot flushes at night but has not been unduly affected by these. She
has felt more depressed recently, feels her skin is ageing fast and that sexual relations with her
husband have become more and more sporadic. She has talked to several friends who use HT
and they say that they believe that hormones improve their quality of life. She wonders if she
should try this therapy.
Tick for the advice you will give to the patient:
- I would recommend therapy
- I would neither recommend nor advise against therapy
- I would not recommend therapy
- I would strongly advise against therapy.
The response variable was recalculated into two categories, so that doctors who 
recommended treatment were compared to those who advised against or were neutral.
Clinical example 2:
Woman, 60 years old, no special risk factors, has used HT for about 5 years and wishes 
to continue because she feels that the therapy improves her quality of life.
Tick for the advice you will give to the patient:
- I would recommend continued therapy
- I would neither recommend nor advice against therapy
- I would not recommend continued therapy
- I would strongly advise against continued therapy.
The response variable was recalculated so that doctors who recommended therapy
were compared to those who advised against or were neutral.
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HWC study 
The dependent variables in the HWC were partly composite and partly derived 
variables, based on the preparation of the data described earlier. The questions regarding 
menstruation and menopausal symptoms are given in section Questionnaires (Box 1).
Age of menopause and menopausal status 
Based on the indication of regularity of menstruation (yes or no) and last 
menstruation, an algorithm was constructed to identify the wave for FMP for the 
individual women who had reached menopause, and censoring date or year for those who 
had not reached menopause. The algorithm defined a retrospective period of 12 months or 
more for the establishment of an FMP wave. Doing this, six cases had given no
indications of last period and were processed manually. Following this, the menopausal 
status for the participants in the specific wave was established (pre- or perimenopausal or 
postmenopausal).
Menopausal symptoms 
The vasomotor symptoms (hot flushes and sweats/night sweats) were given both 
as frequency and burden of symptoms. Vaginal dryness was also given in these two 
modalities. Frequencies were reported as “daily”, “weekly”, “monthly” or “never/almost 
never”. Burden of symptoms was reported as “very much”, “considerably”, “a little” or 
“not bothered” (Box 1).
In the logistic regression analyses of symptoms, a secondary variable of hot 
flushes frequency was used (Paper III). Here, the maximum frequency of HF reported in 
any wave was recorded and given in three categories: daily, 1-4 times per month, or 
never/seldom. Thus, women who had reported daily HF any time during the observation 
period could be compared with women who had reported HF only 1-4 times per month or 
never/almost never during the same time span.
Use of HT 
The dependent variable in the HT analysis (Paper IV) was based on the response 
to the question: Do you use hormones to prevent menopausal symptoms? The response 
alternatives Wave 1: yes – no. Wave 3 – 6: yes – no – used before.
Wave 7: yes – no, never used – used before; how long: ___year ___months.
How old were you when you started HT? ___year.
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In Wave 7: (If stopped) Why did you stop HT? Response alternatives:
I had side effects
I was worried about possible side effects
No longer needed
Other reasons:……. 
In the analysis of factors associated with HT, use of HT was either constructed as 
an ever vs. never use variable (registered in any wave) or used simply as a wave-specific
variable. In order to stratify the HT users in different categories, two new variables were
constructed on the basis of the registration of HT use during the time span. The duration 
of HT variable had three categories: Long-term use (HT in two or more waves), short-
term use (HT in one wave only), and no-use of HT. Because we had recordings of HT use 
at two years interval and had no indication of HT use between the waves, it was not 
possible to allocate these values to an exact number of years of HT use. Use in one wave 
could indicate at least one month and up to four years of HT, while use in two waves 
indicated more than two years of HT. Based on the responses of HT start and duration of 
HT given in Wave 7, we have assumed that HT in one wave usually indicate 1-3 years of 
HT and that HT in two waves or more indicate 3 years or more of HT use as a rule, and 
that the long term users on average use HT longer than the one-wave users.
The second constructed variable related start of HT to the menopausal status, and 
was constructed on the basis of reported start of HT and the menopausal status allocated 
for each woman according to the algorithm described earlier. We decided to compare 
women who started pre- or perimenopausal (from premenopause and up to one year after 
FMP) with women who started postmenopausal, i.e. more than one year after FMP.
74
Independent variables
The independent variables used in the different papers are shown in Table 11.
Table 11. Independent variables used in the studies.
Study Domain Independent variables
Paper 
number
I II
GP study Demographics Age x x
Gender x x
Years in practice x
List size x
Community type x
Part of country x
Practice patterns and 
attitudes
How often discuss HT with patients x
Difficult to give advice x
Having a rule for treatment duration x x
HT implies medicalisation x x
More/less restrictive x
HT improves sex life x
HT protects against myocardial 
infarction
x
HWC 
study Domain Independent variable
Paper 
number
III IV
Demographics Age x x
Civil (marital) status x x
Education x x
Family income x
Community type x
Health factors Self-rated health x
Body mass index x x
Physical activity x x
Daily smoking x x
Alcohol consumption x
Menopausal and 
reproductive factors
Menopausal status x
Hot flushes x
Menarche age x
Parity x
GP study 
Independent variables that were integrated in the models were: gender, age, if the 
GP had a general rule for treatment duration, changes in practice attitude, attitude to:
whether HT implies medicalisation; whether HT leads to improvement of sex life; 
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whether HT gives protection against myocardial infarction. All variables were included in 
the multivariate models and are shown in the tables. 
Age 
The doctor’s age was used as a continuous variable in the logistic regression 
analysis of attitudes to indications and contraindications (Paper I, Table 4) and attitudes to 
treatment (Paper II, Table 4 and 5). We also tested the significance of age (both as 
continuous variable and in age groups) in the other logistic regressions analysis.  
Experience as GP 
The doctor’s experience as a GP was included in the questionnaire.  Experience 
was measured as number of years in general practice (part- time or full time). 
Size of patient list 
Many GPs work part time, and a full time list is supposed to have 1500 patients. 
The size of the patient list was fixed in four groups: less than 500, 501 – 1000, 1001-1500
and greater than 1500.  
Community size and location 
The size of the community was preset in three categories: City (> 20 000
inhabitants), small town (tettsted) (5-20 000 inhabitants) or rural practice (< 5000 
inhabitants). Norway has traditionally been divided in 5 parts: Eastern, Southern 
(Sørlandet), Western, Mid-Norway (Trøndelag) and Northern Norway and this were 
followed also in our survey. 
Practice patterns and attitudes 
In the first question, we asked the physician to indicate how frequently HT was 
discussed: How often do you discuss HT with patients? The response alternatives were: 
Less than once per month, 1-4 times per month, 1-3 times per week, or almost every day.
Here, the response alternatives were divided in two categories in the analyses: Almost 
every day vs. weekly or less. Second, we asked the doctors to think about the task of 
giving advice: Do you experience that it is difficult to give advice (consider benefits and
risks) regarding HT? The response alternatives for the second question were divided in 
five categories: No, never – Seldom – Occasionally – Often – Yes, always. In the analysis, 
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the response was grouped in three categories: Never and seldom, occasionally and
Often/always.
Regarding treatment duration, the question do you have a main rule for duration 
of HT when treating menopausal symptoms? With the response alternatives yes or no
was used in the analysis.
Three of the attitudes to HT questions were used in the regression analysis. The 
attitude to the medicalisation statement was used in the analysis of factors influencing 
some of the indications and contraindications, and when the doctors gave advice in the 
clinical examples. Also, the attitude to the statement that HT improves sex life and HT 
protects against myocardial infarction were used similarly. The response categories were 
grouped in three alternatives in the analyses: Agree (mostly+somewhat), disagree (mostly 
+ somewhat) and neutral.
At last, the question “Have you changed your practice when prescribing HT the 
last 1-2 years?” was used in the analyses. The response alternatives were grouped in “as 
previously” and “more restrictive”.
HWC study 
The baseline data in HUSK 1997-98 consist of these variables used in the analyses:
- Sociodemographic: Age, civil status, family income, education level, dwelling 
community.
- Self-rated health (overall feeling of health): Excellent, good, not so good, bad.
- Age at first menstruation (menarche age).
- Number of children (parity)
- Life style (habits): Smoking, alcohol consumption, physical activity.
Age 
The women in HWC were born 1953-1957, so the age span of the respondents 
was five years. They were 40-44 years at baseline, and 53-57 years in Wave 7. The 
variable was treated as a continuous variable in the analyses.
Civil status 
In HUSK, the response alternatives were married, living in partnership, living 
single, being widow, being separated or divorced. This was not asked for in the HWC, so 
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we do not have information about changing of the civil status during the time span. In the 
analysis, the variable was grouped in three categories: married/partnership, single/widow, 
separated/divorced.
Family income (per year) 
This was based on self report, and not asked for later in the cohort. The HUSK 
recording was very detailed, with nine intervals starting with NOK 0-50 000. In the 
analyses, the women were grouped in three categories: low (< NOK 200 000), medium 
(NOK 200 000 – 399 000) and high (> NOK 400 000). 
Education 
The question in HUSK was rather detailed, with 7 categories. In the analysis, the 
variable was recoded to contain three categories: Low (elementary school or less), 
medium (lower and upper secondary school) and high (bachelor or master degree). 
Community type 
The HWC participants were registered with a code for the dwelling municipality. 
Based on a definition of centralization used in the Norwegian Central Bureau of Statistics, 
the municipalities were divided into rural or central.  
Self-rated health  
The question “How is your health status now?” is widely used in Norwegian 
population based health surveys, and is a reliable predictor of mortality in the 
population165. The response alternatives were bad, not so good, good, excellent. In the 
analyses, the response alternatives have been dichotomized in bad/not so good and 
good/excellent. In Paper III, the variable has also been used as a dependent variable in a 
two-way correlation test (X2 test). 
Age at first menstruation (menarche age) 
This was reported at HUSK baseline, and is of course subject to recall bias, being 
reported some 30 years after the event. On the other side, as a significant event in most 
women’s life, we can assume that it is often remembered quite exact. In the analysis, the 
ages have been grouped in three categories: Early (< 12 years), medium (13-14 years) and 
late (> 15 years). 
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Parity 
The women stated the number of children in HUSK, and this was not asked for 
later. Some of the women may have given birth at a later stage. In the analysis, the 
variable has been grouped into zero (no children), one child, two children, and three or 
more children.
Alcohol consumption 
In HUSK, the women were asked if they used alcohol or not, the type of alcohol 
mostly used (beer, wine or liquor), and to quantify the consumed amount in alcohol units 
(1 unit = 1 glass of wine). We used the quantified amounts given, grouped in four 
categories: no use, 1-2 units per month, 3-7 units per months, > 8 units per month. 
Physical activity 
In HUSK and HWC, physical activity was registered both in a light activity 
variable and a hard activity variable. Physical activity was specified for activity in the last 
year (outside work, but activity during travelling to and from the job included), estimated 
as a mean per week the last year. Both questions should be answered:
- Light activity (not sweating/out of breath): none - < 1 hour – 1-2 hours – 3 or 
more hours.
- Hard activity (sweating/out of breath): none - < 1 hour – 1-2 hours – 3 or more 
hours.
In the logistic regression analysis of the frequency of symptoms (Paper 3), the 
hard activity variable was used and dichotomized into more or less than 3 hours.
In addition, HUSK contained a composite physical activity variable which was 
used in the regression analysis of HT use (Paper 4). Here, regular physical activity was
divided in two groups: no regular activity or regular activity with t3 h light activity and 
t1 h intense activity per week.
Daily smoking 
This was asked for both at baseline and in every wave of the HWC. The response 
alternatives were yes or no, and for those who answered yes, we also asked for the 
number of cigarettes daily. The latter variable was not used in the analyses. Updated 
smoking information was used to get more valid data regarding smoking. In Wave 1, a 
number of respondents were missing and we assumed that if some of these respondents 
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later reported to be daily smokers they had probably smoked also at baseline. We also 
found that a number of the respondents reporting not daily smoking in Wave 1 later 
reported daily smoking in some of the other waves. Since the prevalence of daily smoking 
has been falling the last 10-15 years in Norway, we assume that these responders had 
been previous smokers, reporting not daily smoking in Wave 1 but starting again later. As 
a result of this, the prevalence of daily smoking in wave 1 or later was 39.9 %, contrasting 
the prevalence in wave 1 only of 33.4 %.
Menopausal status 
Menopausal status was used as an independent variable in the logistic regression 
analyses of HT use in Wave 1, 4 and 7 (Paper IV, Table 4). The variable has been
described earlier (section Dependent variables). 
Menopausal symptoms 
Frequency of hot flushes (both wave-specific and the secondary calculated
variable described earlier - section Dependent variables) was used in the HT analyses on 
Paper IV (Tables 2-4).
GP Study statistics
Summary statistics were used to describe proportion of doctors who agreed or 
disagreed to the statements regarding effects, indications and contraindications. Analysis
of correlations was conducted using correlation tests (Pearson, Spearman). Variables that 
were associated with response categories for the statements and indications and 
contraindications were further analyzed using logistical regression, and the answer 
categories were dichotomized as described in the previous chapter (dependent variables).
In the analysis, the following significant and/or clinical relevant variables were included: 
age, gender, number of patients on list, municipality type, region, how often the doctor 
discussed HT with patients, whether the doctor thought it was difficult to give advice, 
whether the doctor had a general rule for duration of treatment, and the doctor’s stance on 
the question of medicalisation. We also performed analysis where the outcome variable 
was grouped in “no emphasis” vs. “great emphasis” and “less emphasis” combined.
To analyze attitudes to HT in the clinical examples, the «Would recommend HT»
group was tested against the «Would not recommend HT» group on its own and together 
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with the «Would neither recommend nor advise against HT» group. An analysis of those 
who did not recommend HT was carried out and this was tested vis-à-vis the other two
groups combined. 
The level of significance was set at p < 0.05. The data were processed using 
Version 12 and 14 of the SPSS statistical package. 
HWC statistics
Symptoms and age at menopause 
Summary statistics and frequencies were used to describe point prevalence and 
distribution of vasomotor symptoms and vaginal dryness as reported in the seven 
questionnaires.
The mean and median age of menopause (FMP) was estimated by Kaplan-Meier 
survival analysis. Cox regression was used to test the influence of independent variables 
(smoking, menarche age and parity) on FMP. 
In order to identify the number and distribution of women with different degrees 
of symptoms during the observation period, we also performed a longitudinal analysis of 
women reporting frequent (daily and weekly) hot flushes. Onset and duration of hot 
flushes, and relation to FMP were analyzed.
To analyze independent variables associated with the frequency of hot flushes, we 
used multinomial logistic regression. Each woman’s maximum value of hot flushes 
during the observation period was obtained and recoded into: daily, 1-4 times per month, 
and never/seldom. Factors known from the literature as potential predictors of vasovagal 
symptoms, or that from a clinical point of view might influence the degree of symptoms, 
were considered for inclusion in the model: age in last wave, daily smoking at baseline or 
during the observation period, body mass index groups (kg/m2), alcohol consumption, 
level of exercise, self-rated health at baseline, menarche age, marital status, parity, family 
income and educational level. Furthermore, the model was successively reduced by 
removal of non-significant variables, previously excluded variables were reconsidered as 
possible confounders, and some hypothesized interaction effects were tested for, all 
according to Hosmer’s methodology166. The final model included clinically relevant non-
significant variables and is shown in Paper III, Table 4.
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The association between symptoms and self-rated health in each wave was 
evaluated using Spearman’s correlation coefficient (rho). The statistical package used was 
SPSS (v.18). 
Use of HT and factors associated with HT use. 
In the prospective, longitudinal analysis, the frequency of current users 
(prevalence) and the frequency of new users (two-year incidence) were determined for 
each wave (Paper III, Table 1). The incidence of new users was defined as HT users who 
did not use HT in the preceding wave, which was divided by the number of women “at 
risk,” i.e., the number of respondents minus the HT users in the preceding wave.  Thus, 
some of the women “at risk” (in the denominator) might have used HT in one or more of 
the other previous waves.  The duration of HT treatment was based on the responses to 
the questions related to the start of HT and the treatment duration (years and/or months) 
in Wave 7. We determined the mean age of starting HT, the distribution of the starting 
age, and the relationship to FMP by calculating these values based on the responses given 
in the different waves. The values were adjusted accordingly if respondents answered the 
question (in Wave 7) related to their age when starting HT.
To check for possible responder misinterpretations of the HT questions (systemic 
HT use or not) in the questionnaire, we also performed a manual comparison of these 
responses and the medication list (the last question in the questionnaire) in Wave 7.
We analyzed independent variables that were possibly associated with HT use during the 
observation period by applying binary and multinomial logistic regression. In the binary 
logistic regression, the dependent variable was HT use during the observation period or in 
a specific wave, i.e., ever vs. never using HT. In the multinomial analysis, the HT users 
were grouped into two categories: short-term use (HT reported in one wave only) and 
long-term use (HT reported in more than one wave). Also, HT users who started in pre- or 
perimenopause (before FMP or less than one year after FMP) were compared to those 
who started in post-menopause (one year or more after FMP). The analyses also included 
factors reported in the literature as possible predictors of use,167,168 as well as the 
participant’s background (socioeconomic) and clinically plausible factors. These factors 
are listed in Tables 2 and 3 in Paper IV. Possible confounding variables and interactions 
were examined using the methodology described earlier. We also performed separate 
analyses of three different waves (Waves 1, 4, and 7) to examine trends over time and 
possible variations in the contributions of different predictors. For time trend analyses 
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(Paper IV, Table 1, Fig 1) and differences by wave (Table 4), we applied McNemar’s test 
and formal tests of interactions by time to provide statistical evidence of secular trends.
Case-control substudy based on propensity scores 
We studied the frequency of the reappearance of menopausal symptoms after HT 
discontinuation using a sub cohort where the HT users in Wave 4 were matched with 
nonusers in the same wave based on their propensity scores, which were calculated with 
the SPSS propensity score syntax produced by Levesque and Painter169. The propensity 
score was the propensity (from 0 to 1) of receiving a treatment given a set of known 
variables. The method is used to adjust for potential selection bias, confounding, and
differences between treatment groups in observational studies170. The HT propensity 
scores in Wave 4 were estimated for each woman using binary logistic regression with the 
following variables as predictors: menopausal stage (Wave 4, categorized in quintiles); 
HT use in the previous wave (Wave 3); summed score for symptoms in the previous wave 
(Wave 3); and the two-way interactions between menopausal stage and HT use,
menopausal stage and symptoms, and HT use in Wave 3 and symptoms. Comparisons of 
symptoms in later waves between the users in Wave 4 and their matched controls were 
performed using Wilcoxon non-parametric signed rank test. A small number of the 
controls started using HT in later waves, which could have blurred the differences. Thus, 
we conducted the analyses with and without these pairs.
The means, proportions, and odds ratios (OR) are given with 95% confidence 
intervals (CI), as appropriate. SPSS version 20 was used to perform all of the statistical 
analyses.
Ethics and approvals 
The Norwegian Data Directorate and the Regional Committee for Medical 
Research Ethics approved the HWC cohort. All participants provided written informed 
consent to their participation in the study.
Since the GP study consisted of a questionnaire survey obtained and treated 
anonymously and no patients were involved, it was not necessary to obtain approval from 
the Research Ethics Committee or the Data Directorate for this study.
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Synopsis of the Papers 
Paper I
Bjørn Gjelsvik, Elisabeth Swensen, Per Hjortdahl.
The general practitioner’s view on hormone replacement therapy during and after 
menopause. [Allmennlegenes syn på hormonbehandling i og etter overgangsalderen.]
Tidsskr Nor Laegeforen 2007; 127:2000-3. Article in Norwegian. English version can be 
downloaded from the journal.
Background. The publication of the US-based WHI study and other studies in 2002-2003
profoundly changed the evidence base for treatment, and as a result also Norwegian 
recommendations for treatment were altered in 2003.
Objectives. The aim of the study was to investigate Norwegian GPs’ attitude to hormone 
replacement treatment in menopause, their knowledge of current guidelines, effects and 
indications, the risk of side effects, and the personal use of hormone treatment by female GPs.
Material and methods. A questionnaire was sent to 400 Norwegian GPs, randomly drawn 
from the membership list of GPs in the Norwegian Medical Association, in May 2004. Perception 
of treatment effect of HT was evaluated by means of a scale of 1 to 5 to show the extent of 
agreement or disagreement with a given statement. Response to these statements was studied 
with logistic regression, and doctors who answered “mostly” or “somewhat agree” were 
compared to those who answered “disagree” or were neutral. Emphasis on factors that could 
indicate or contraindicate HT was evaluated by a scale with three grades: Great emphasis, less 
emphasis, no emphasis or don’t know. The doctors who placed great emphasis on the indication or 
contraindication were compared with the doctors who placed little or no emphasis on it. The 
response categories were dichotomized and the associations assessed by means of logistic 
regression. 
Results. We received answers from 72 %. 30% of the respondents were women. The 
average age of all respondents was 46 years (range 26–69 years), the average number of years in 
practice 14 years (range 1–37 years). 96 % of the doctors agreed that HT increase the risk of 
breast cancer. 
72% agreed with the statement that HT improves sex life and 40 % agreed that it delays aging of 
the skin. 67% disagreed that HT provide protection against cardiac infarction. 33 % of the doctors 
agreed to the statement that HT lead to an unfortunate medicalisation of a natural phase in 
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women’s life, while 44 % disagreed and 24 % had a neutral position on this statement. The 
attitude to this question was not related to age or gender.
One out of four GPs did not have a general rule for treatment duration. The majority 
would treat for less than 5 years. Female doctors had higher odds for having a rule, compared to 
male.
Bothersome hot flushes were the major indication for treatment. Also risk for 
osteoporosis, mood variations, vaginal dryness and loss of libido was considered important 
indications. Of contra-indications, 98 % put great emphasis on history of breast cancer. Genetic 
disposition of breast cancer, thrombo-embolic disease and cardiovascular disease was also 
considered important contra-indications.
Female GPs seem to be better updated on some aspects of the treatment than men. 14 out of 17
(82 %) of peri- and postmenopausal female GPs were using or had used such treatment.
Interpretation. The answers imply that most Norwegian GPs knew the current evidence 
base regarding the effects, indications and side effects of hormone therapy. The fact that 
vasomotor symptoms was regarded as the dominating indication, and that most doctors had a rule 
for treatment duration indicate that the majority of doctors knew and applied the 
recommendations. Compared to female GPs, male doctors seemed less updated on the field. 
Given the uncertain documentation and unclear communication of some of the effects, it may 
appear that HT’s assumed positive and non-specific significance for «the female aspect » is 
assigned greater importance in the clinical decision-making process.
The proportion of menopausal female GPs who used or had used hormone treatment 
themselves had remained quite stable since the 1990s and was substantially higher compared to
the general female population in Norway. This finding may imply that menopausal female GPs 
regarded the risks of treatment as low, and that most of them found the benefits of treatment 
greater than the risks.
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Paper II
Gjelsvik B. 
General practitioners' advice on menopausal hormone therapy.
[Allmennlegers råd om hormonbehandling i overgangsalderen.]
Tidsskr Nor Laegeforen 2008 Aug 14;128(15):1660-3. Article in Norwegian. The English 
version can be downloaded from the journal.
Background. One aspect of prescribing HT is related to the consideration of risk 
and uncertainty. Increased risk of breast cancer and cardiovascular disease must be 
weighed against the benefit of the treatment. When the evidence base for treatment 
recommendations becomes more reliable, doctors may be more active in giving advice in 
favor of or against treatment.
Aims. The purpose of the study was to investigate Norwegian GPs’ perception of 
their own role with respect to prescribing HT to menopausal and post-menopausal 
women, and the background factors for the decisions doctors make when giving advice. 
Method. A questionnaire with a total of 17 main questions and six background 
variables was sent to a random selection of 400 Norwegian GPs in 2004. Three of the 
questions in the questionnaire were formulated as clinical examples where doctors were 
requested to give an opinion about whether they would advise using HT or not, and they 
could also give their own comments. Analysis of correlations was conducted using 
correlation tests (Pearson, Spearman). Variables associated with recommending treatment 
were analyzed using logistical regression.
Results. We received answers from 72 %. 30% of the respondents were women. The 
average age of all respondents was 46 years (range 26–69 years), the average number of years in 
practice 14 years (range 1–37 years). 13% answered that it was usually the doctor who took 
the initiative to start HT. Those who disagreed that HT implied medicalisation had a 
significantly greater tendency to believe that the doctor takes the initiative to start the 
therapy (OR 2.5: 95% CI 1.1–6.4). 29% answered that the doctor most often took the 
initiative to discontinue the therapy. Doctors who agreed that HT implies medicalisation 
were more likely to take the initiative to discontinue the treatment (OR 2.7; 95% CI 1.3–
5.4).
91% were of the opinion that it was vital to know the risks of HT. Almost two-
thirds of the doctors thought that the “number needed to harm” – i.e. how many must 
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receive treatment in a given period of time for one person to suffer a serious side-effect –
provided most information. 91% of the doctors felt that risk had considerable or some 
importance.
When doctors were requested to give an opinion on clinical examples, they 
were clearly divided when it came to giving advice. The likelihood of recommending 
therapy was four times higher among the doctors who did not agree that HT implied 
medicalisation compared with those who agreed with the statement. There was no 
correlation with other background variables, perception of indications or 
contraindications or perception of risk associated with therapy.
Interpretation. The study indicates that many doctors regarded themselves as 
active in giving advice, to a greater extent than might be anticipated beforehand; given 
that HT is primarily the woman’s own choice. The majority of doctors was more 
restrictive and believed that the therapy implies a risk of serious side-effects.  It is 
interesting to note that the GPs’ perception of the significance of risk is not reflected in 
the clinical examples. This may indicate that doctors do not integrate the perception of 
risk indicated in this manner in their internal dialogues when giving advice on HT.   The 
doctors’ attitude to the question of whether the treatment implies medicalisation was more 
crucial for the advice they gave than their perception of indications, contraindications and 
the effects of treatment. 
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Paper III
Gjelsvik B, Rosvold EO, Straand J, Dalen I, Hunskaar S. 
Symptom prevalence during menopause and factors associated with symptoms and 
menopausal age. Results from the Norwegian Hordaland Women's Cohort study.
Maturitas 2011 Dec;70(4):383-90.
Background. Symptoms most consistently connected to changes in hormonal 
status during the menopause are the vasomotor symptoms (hot flushes and sweats/nights 
sweats) and vaginal dryness. Results from cross-sectional and longitudinal cohort studies
vary considerably on many parameters, e.g. menopausal age and degree of symptoms. 
Also, factors associated with symptom prevalence and symptom burden vary in a number 
of studies.
Objectives. To describe symptom prevalences over time during the natural 
menopausal transition, to investigate factors associated with frequency of symptoms as 
well as their possible influence on self-rated health and to estimate age at menopause and 
possible factors associated with this age.
Material. 2229 women aged 40-44 years at baseline, randomly selected from a 
national health survey in Hordaland County, Norway, and followed with seven postal 
questionnaires from 1997 to 2010. Data for 2002 women (90 %) were eligible for 
analyses. The dependent variables were frequencies and burden of the main vasomotor 
menopausal symptoms: hot flushes and night sweats/cold sweats. Self-reported vaginal 
dryness/soreness was also included in the analysis.
Methods. Summary statistics were used to describe point prevalence and 
distribution of vasomotor symptoms and vaginal dryness as reported in the seven 
questionnaires. To analyze independent variables associated with the frequency of hot 
flushes, we used multinomial logistic regression. The association between symptoms and 
self-rated health in each wave was evaluated using Spearman’s correlation coefficient 
(rho). The mean and median age of menopause (FMP) was estimated by Kaplan-Meier 
survival analysis. Cox regression was used to test the influence of independent variables 
(smoking, menarche age and parity) on FMP.  
Results. The proportion of women who experienced daily hot flushes increased 
from 2 % in the 41-42 years age group, to 22 % in the 53-54 years age group, with a 
slight decrease to 20 % in age group 55-57 years. The prevalence of cold sweats/night 
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sweats followed a similar pattern, whereas the proportion of women who reported daily 
vaginal dryness/soreness was considerably lower – from 1 % to 8 % during the time span.
The prevalence of bothersome symptoms showed a similar distribution over the 
age span: The prevalence of considerably and very much bothered reached 21 % and 19
% in the 53-54 year age group for hot flushes and sweats/night sweats respectively and 11 
% in the 55-56 year old women for vaginal dryness.
In a longitudinal analysis, 36 % of the women reported daily hot flushes in one or 
more questionnaires, whereas 29 % did not experience hot flushes at all. The data showed 
a wide variation in onset, increase and decrease of symptoms.
The mean number of years between FMP and reported maximum frequency of hot 
flushes was 1.74 years (SD 3.37 years).  Thirty-five percent reported their first top value 
more than two years after FMP. One out of ten women reached this degree of symptoms 
four or more years after menopause.
Three out of four women with daily hot flushes (20 % of the Cohort) reported this 
frequency of symptoms in one wave only, 8 % in two consecutive waves and 8 % in more 
than two waves. Twenty-eight women (1 % of the Cohort) reported daily hot flushes in 6 
or 7 waves.
Odds for reporting daily hot flushes was higher for smokers compared to women 
who did not smoke: OR = 1.6 (1.24-2.10). Women in the lowest education group also had 
higher odds for reporting daily hot flushes compared to women with a university degree:
OR = 1.8 (1.21-2.56).
There was no association between vasomotor symptoms and physical exercise,
self-rated health, BMI, family income, parity or menarche age as recorded at baseline.  
We found an association between prevalence of vasomotor symptoms and self-
rated health in each wave, indicating that frequent symptoms influenced QoL. 
The mean age for Final Menstruation Period (FMP) in the cohort was 51.1 (50.9-
51.3) years. Smokers had a mean age of FMP 0.9 years earlier compared to the non-
smokers.
Conclusions. About one-third of Norwegian women report frequent and 
bothersome vasomotor symptoms during the menopausal transition. Daily smoking and 
educational level were independent risk factors for experiencing daily menopausal 
symptoms. Degree of physical exercise, BMI, parity or menarche age did not have 
significant influence. 
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Paper IV
Gjelsvik B, Straand J, Hunskår S, Dalen I, Rosvold EO. 
Use and discontinued use of menopausal hormone therapy in healthy women in 
Norway. The Hordaland Women’s Cohort (HWC) study.
Accepted for publication in Menopause, the Journal of the North American Menopause 
Society.
Background. Studies published shortly after the turn of the millennium showed 
that HT did not prevent cardiovascular disease, and also led to increased risk of breast 
cancer. According to Norwegian recommendations published in 2003, HT should only be 
prescribed for menopausal vasomotor symptoms with significant negative effects on a 
woman’s quality of life, and the treatment should be revised annually. No efforts, 
however, were undertaken to implement these recommendations among the physicians. 
Objective. To explore HT use and possible association with self-rated health 
among users and no-users during the menopausal transition, to analyze the duration of HT 
use, its relationship to age and menopausal stage, and to identify predictors for HT use. 
We also examined how often menopausal symptoms reappeared in women who stopped 
using HT.
Material and methods. In 1997, 2229 women aged 40-44 years were selected 
randomly from a national health survey in Hordaland County and followed up with seven 
postal questionnaires during 1999-2010. Data from 2002 women (90%) were eligible for 
analysis. Summary statistics and multiple logistic regressions were used. We studied the 
reappearance of symptoms after HT discontinuation using a sub cohort based on their 
propensity scores, which comprised 134 matched pairs of cases (HT users) and controls 
(nonusers).
Results. The two-year incidence of new HT users dropped significantly from 8.2 
% (95 % C.I. 7.0-9.5) in 2002 to 4.3 % (95 % C.I. 3.4-5.2) in 2004 and remained stable
despite an increasing prevalence of bothering symptoms in the cohort.  At the same time, 
the prevalence of women reporting self-rated health as bad or not so good was stable. The 
prevalence of HT use increased slowly from 11.5 % in 2002 (age 43-47 years) to 12.7 % 
in 2010 (age 53-57 years). 29.5 % (27.5-31.5) of the participants reported use of HT in 
one or more questionnaires. 
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For those who had reached menopause by 2010, FMP was the median year of 
starting HT. The mean duration of HT use was 4.5 years (95 % CI = 4.0-5.0 years). 
Odds for HT use was higher among women with daily hot flushes compared to 
those who never or rarely experienced them (OR = 3.2, 95% CI = 2.3-4.4).  Older age at 
baseline, being postmenopausal, being smoker and reporting self-rated health bad or not 
so good in Wave 1 was also associated with higher odds for using HT.
After HT cessation, hot flushes were still present and the frequency did not differ 
from the untreated controls.
Conclusion. HT use among pre-, peri and early postmenopausal women in 
Norway was lower than reported in other Nordic and Western studies in the same period. 
The severity of vasomotor symptoms, mainly hot flushes, was the main reason for HT use 
and most women stopped treatment within five years. Most women experienced 
reappearance of symptoms after treatment cessation. The low prevalence of HT use 
confirms that many Norwegian women prefer to live without HT throughout the 
menopausal transition, despite troublesome symptoms. The use of HT was by large in line 
with the Norwegian recommendations, and our data do not support that the relatively low
prevalence of HT use impaired the quality of life among the women in cohort. 
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General discussion. 
Methodological considerations.
In population-based surveys, the assumptions to consider deals with the external
and the internal validity of the study171. The external validity has to do with the 
generalization of the results – that is: can the results be applied to an external, general
population? In our studies: Can the results be applied to other GPs, for example in the 
Nordic countries or in Europe? Regarding the results from the HWC study: can the results 
be applied to the Norwegian female population of the same age, and to female 
populations in other countries? The question is: How representative is the population
from which the study respondents have been selected?
Internal validity deals with the validity of the inferences in the population from 
which the information has been sampled. It depends on the selection of subjects, the 
quality of the information obtained, and confounding variables. 
This study consist of a cross-sectional study (the GP study) exploring knowledge, 
attitudes and factors associated with prescription of HT, and a longitudinal cohort study
(the HWC study) exploring symptoms, risk factors and use of HT in a female population.
In cross-sectional studies, it is in general not possible to make assumptions about
causality. We therefore restrict ourselves to report correlations, e.g. between attitudes 
regarding the medicalisation question and the advice given. It is, however, reasonable to 
assume that more comprehensive attitudes predict standing when a specified case history 
is presented. Such attitudes can be regarded as a kind of explanatory variables in the 
realm of human decision making. Cross-sectional studies will often lead to hypotheses 
regarding risk factors or explanatory variables for a specific outcome, e.g. prescription of
HT.
In a foreword in Acta Obstetricia et Gynecologica Scandinavica, Collins and 
Landgren pointed out that most of our knowledge of the menopause is based on women 
who seek medical attention for their climacteric symptoms172. The authors asked for 
longitudinal studies drawn from the general population, allowing changes to be detected 
from year to year through the menopause. The design of the HWC study meets most of 
the demands put forward by these researchers. In order to advance from associations to 
causality, studies with longitudinal assessment of exposure are necessary, e.g. cohort 
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studies. In a cohort study, it is possible to register an exposure at a specific time point or 
period, register an outcome later and compare individuals with and without an exposure 
with respect to the outcome. In addition, the association should be biologically plausible. 
As an example, it is plausible that the association between daily smoking at baseline and 
later reporting of more hot flushes (or earlier menopause) is causal, since the time span 
condition is fulfilled; there is a biological plausible explanation and the regression model 
control for other possible explanatory variables and confounders. In a cohort study, the 
internal validity of the measurements usually is most important when assumptions on 
causality are considered.
Internal validity in the GP Study 
In the GP study, we invited 400 doctors, approximately 11 % of the GP population 
in Norway. The total response rate was 76 % and the sample used represented 72 % of the 
invited doctors. The response rates in other cross-sectional surveys in the NMA database 
has been in the same range (70-73%) although some questionnaire surveys among GPs
have had up to 90 % response rate173. The GP sample had fewer doctors in the oldest age 
group (Table 7), but all taken together we regard that the proportion of important 
characteristics (age, gender, practice location) of the sample used is quite similar to 
figures in the GP database of the NMA (A. Taraldseth, NMA, personal communication).
We therefore conclude that the GP sample is representative for the GP population in 
Norway, and the risk for systematic selection bias is neglectable.
Information bias may occur in our study due to misinterpretation of the questions 
in a systematic manner. We performed a pilot test of the questionnaires in two groups of 
GPs. Based on the experience from these groups and further discussion in the writing 
group of Paper I the final questionnaire was constructed. There were few missing values 
in the returned questionnaires, which indicate that the questions were relevant and easily 
understood by the doctors. Also, in the pilot testing a common comment from the GPs
was that the questions were easy to understand. It was also possible for the GPs to submit 
comments in free text on several of the questions and the clinical examples. These 
comments were checked and did not reveal any evidence of systematic misinterpretation.
On this background, we regard that the knowledge and attitudes of Norwegian 
GPs regarding HT are reflected in the study. However, a limitation in questionnaires is 
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that they capture what doctors says about the statements (and the alternatives they tick off 
in the cases), and not necessarily what they do in the clinical situation. The measured 
results in the study are what the GPs declare they will do given a set of assumptions. In a 
clinical situation, many other factors will contribute to the final decision to prescribe or 
not. Among these are additional information on symptoms, evaluation of other risk 
factors and assessment of the woman’s preferences.
External validity in the GP study. 
Approximately 95 % of the medical doctors in Norway are members of the NMA, 
so there are a number of GPs (fastleger) from which a random sample has not been 
drawn. The NMA register had 3654 GPs per 1.3.2004, while the number of GPs
(fastleger) recorded in the Norwegian Health Directorate database per 31.12.2003 was 
3713. The NMA register is updated (regarding addresses etc) and is used for several other 
research purposes, and we regard that the small number of GPs not included in the NMA 
database does not violate the representativity of the study sample. However, regarding the 
possibility of generalizing the inferences to GPs in other western countries is somewhat 
restricted. As to the Nordic GPs, there is a long tradition of scientific collaboration. The 
joint ownership of the Scandinavian Journal of Primary Health Care and the Nordic 
Conferences for GPs held biannually are examples. Also, the Norwegian and Swedish 
Medical Agencies have collaborated for many years with respect to guidelines for 
treatment in several clinical fields. On the other hand, there may be diverging traditions 
regarding to which extent prescription of HT is done by GPs or by organ 
specialists/hospital doctors in the Nordic countries. But despite some differences 
regarding GPs role in the health system, the clinical tasks are quite similar. It is therefore 
relevant to apply many of the results regarding GPs to a wider, Nordic population of GPs.
Another concern is to which extent the results, which were collected in 2004, can 
be regarded as valid today. In fact, there are few new scientific results regarding effects 
and risks of HT published after 2004. With the exception of reassessment of the WHI 
study139 and the debate regarding the timing hypothesis142, there has been little debate on 
HT in later years. It is possible that on this background, some of the assumed effects of 
HT which were marketed to the GPs before 2002 are unknown among younger GP’s who 
started their work much later. However, our results were valid in 2004, and are probably 
also valid among the majority of GPs today.
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Medical science and treatment recommendations based on scientific research 
emerge rapidly from one corner of the world to another, and both journals and 
conferences contribute to the dissemination of results. But treatment traditions are often
different, and HT is a field of medicine where differences between countries and regions 
of the world exists174. On the other hand, aspects of the decision process and how doctors 
communicate with patients are more universal, and the results presented here concerning 
decision making and adherence to recommendations are relevant in many countries. 
Internal validity in the HWC study 
At baseline, the Cohort consisted of 2229 women, the characteristics of which are 
summarized in Table 8. There were no significant differences between the Cohort and the 
rest of the female participants in HUSK, except for education and annual family income, 
which were slightly higher among females in the Cohort.
There were no significant differences with respect to baseline characteristics 
between the dataset analyzed (N=2002) and the Cohort as a whole (Table 11). The 
excluded individuals (n=227), however, were slightly older, had lower income, were 
more obese and less physically active than those in the dataset analyzed.
The attrition rate in the Cohort has been low. In wave 7, the number of remaining 
participants in HWC comprised 93 % of the original cohort. The response rates in the 
waves have varied between 82 % and 93 %. When the Cohort was constructed, a 
maximum attrition rate of 5 % per wave was used to calculate the size of the Cohort in 
order to get sufficient power. The number of remaining participants in the Cohort in 
Wave 7 is far better, so we can conclude that the representativity and the statistical 
strength of the Cohort has been maintained.
Additional strengths in HWC were the long-term follow-up from before the 
menopausal transition to FMP and postmenopause. A particular advantage is that the 
observation period included observations made before and after the shift in clinical 
guidelines.
The questionnaire was almost identical for each wave. Thus, it was easy for the 
women to recognize the questions and little chance for misinterpreting the questions from 
one wave to the next. 
Some questions had risk for memory bias. In particular, data regarding last 
menstrual bleeding was vulnerable. In a cross-sectional design, the impact of such 
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memory bias will limit the validity of the study. In the longitudinal design, every woman 
acts as her own control. Thus, it was possible to identify cases of possible memory bias.
When these data were used to verify the FMP, it was necessary to check a number of 
responses manually.
The SWAN investigators found that assessing the recall of symptoms during the 
last 14 days had an acceptable sensitivity (78-84 %) and specificity (85-89 %) in a three 
year observation period175. In our study, the symptom question was not specified to the 
last 14-day period. We asked the women to grade the symptoms, both how often
symptoms occurred and to which degree the symptoms were bothering.  When 
respondents are asked to grade the severity of symptoms, the prevalence is typically 
reduced, and this can have led to lower degree of bothering symptoms in our study176. In 
clinical studies, checklist are often used to describe the symptoms. When a checklist is 
used for assessing symptoms instead of open-ended questions, elicitation of positive 
answers may represent a problem.
As concerns symptom reporting, a weakness of our study is the time span between 
each recording of data. It is difficult to estimate the duration of symptoms, since we do 
not know what happens between two waves. Also, since the oldest women in Wave 7 had 
reached the age of 57 years, we must expect that for some of the women in the Cohort, 
the duration of symptoms may be longer. Other recent studies have found that symptoms 
prevail for several years for some postmenopausal women49,55.
Our set of independent variables did not include a number of variables which in 
the Norwegian Menopause Project were associated with symptom burden9. These 
included some psychosocial variables, such as the women’s menstrual coping style, 
mother’s menopausal complaints, negative expectations and social network. Whether a 
subject report suffering from symptoms often, sometimes or never depends upon her own 
frame of reference. Such factors may explain some of the differences between our 
findings and findings from less representative samples.
A limitation in our study is that we did not exclude current or previous HT users 
in the analyses of factors associated with the symptom burden (Paper III). We performed 
a regression analysis with and without the HT users, and the exclusion of HT users did 
not substantially change the results. We therefore decided not to exclude the HT users in 
the data analysis in order to maintain the representativity of the Cohort.
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Some methodological points had to be considered when we compared our HT use 
prevalence figures with other studies. First, we excluded women from analyses who had 
undergone surgical removal of the uterus and/or ovaries. The prevalence of HT use in this 
group was slightly higher than that among healthy women in the HWC. Second, the 
biennial method used for data recording in the HWC led to under-reporting of HT use. A
woman could have used HT for only a short period between two waves, not reporting
current HT use in our biennial questionnaires. In the last wave, 35 more women reported 
previous use of HT, although they had not been recorded as HT users in the preceding
waves. These two factors will contribute to lower estimates of HT use in our study. 
In wave 7, women who had stopped using HT also was asked for how long time 
they had used HT. Women who had used HT for 3 months or less (n=16) were 
categorized as no-users in our survey. This was an arbitrary cut-off, taking into account 
that we wanted to compare HT users with no-users during a time span of more than 10 
years, and use in 3 months or less would represent a negligible part of the time span.
The question about HT use could have been misinterpreted, since we did not 
specify the meaning of systemic (per os or transdermal) treatment. Thus, topical 
applications or low-potency estrogen could be included. A validation of the responses 
was undertaken based on the responses in Wave 7. Approximately 8% of the HT users 
reported the use of topical or low-potency HT only when they listed their medications 
(last page of the questionnaire). The prevalence rate in wave 7 should then be reduced 
with approximately this percentage. All taken together, the possible recording bias went 
in opposite directions and were impossible to quantify exactly, so we decided not to do 
any adjustments.
The exact dates for starting treatment were not determined in our study, so the 
start of treatment was either estimated based on the first time HT use was reported in one 
of the waves or the age reported in Wave 7. This may imply a memory bias. The fact that 
a small proportion of the sample reported start of HT in age before forty years may imply 
that some women had undergone surgery (oopherectomy) without reporting it. We had no
access to medical records to control for this. 
When assessing self-rated health in the cohort, a standard question with grading in 
four categories was used. The question is widely used in other surveys carried out in 
Norway and many other countries, and reflects the responder’s “global” sense of present 
health status. However, the question is not designed to be an instrument for measuring 
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QoL, although there is a positive correlation between self-rated health and satisfaction 
with life177. The simplicity is both an advantage and a limitation: The question is easy to 
interpret and has been validated as a strong predictor of mortality in several 
studies165,178,179. On the other hand, it will not catch aspects and variations in QoL, which 
would have been possible with more detailed and sophisticated instruments. However, 
the impact of symptoms on QoL measurements in observational studies seems unclear, 
given that other surveys have demonstrated lack of correlations between vasomotor 
symptoms and reported QoL56,180,181.
As concerns assessment of symptoms after HT cessation, the study design also
had some limitations. When constructing the propensity score algorithm, the number of 
variables had to be restricted in order to get sufficient power. The design of the case 
control substudy has some limitations, as we cannot be sure that the treatment and control 
groups are identical in all other respects than HT treatment. We did not control for all the 
variables that had an influence in the adjusted analyses (e.g. smoking). However, they 
were comparable as to the most important variables: menopausal stage, sum score of 
symptoms in preceding wave and HT use in preceding wave. Also, the groups were 
smaller when analyzed in wave 5 and 6 due to the procedure per se and a number of 
missing values. Following this, there is a risk for loss of power and that differences 
between the cases and controls do not reach statistical significance in these waves (type 2 
error).
A number of the controls started HT after Wave 4, which could have contributed
to fewer symptoms in the control group after Wave 4 and blurred the differences between 
the groups. We therefore conducted the analyses with and without these pairs, and the 
findings did not differ significantly (data not shown).
External validity in the HWC study 
In the HWC study, the sample was drawn from the female participants in the 
HUSK study 1997-98. The recruitment and characteristics of the HWC participants is 
discussed in another paper from the cohort163. There are great differences in symptom 
prevalence and HT use reported in different parts of the world. To a large extent, these 
differences have been attributed to cultural differences, with different ways of describing 
and conceptualizing female menopause and aging1,30,182, as well as to study design and 
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study sample. Although the Norwegian population gradually has become more multi-
ethnic during the last 20-30 years, we suppose that in the age group represented in HWC 
(women born 1957-61) there are fewer inhabitants of foreign ethnic groups than in the 
younger generation. We do not know the ethnic background of the HWC participants, but 
we have no reason to believe that it differs from the average of Norway, with a 
predominantly white, Caucasian population with Western cultural orientation and 
traditions in this age group. Thus, the results will have relevance to similar populations in 
the other Nordic and Western societies.
The Hordaland Women’s Cohort (HWC) is community based, includes a large 
number of randomly selected participants, and the attrition rate was low, all factors 
strengthening the external validity of the study results. Compared to the US SWAN study, 
the women in the Cohort had a lower prevalence of surgically induced menopause. In 
SWAN, the overall incidence of surgically induced menopause (bilateral oopherectomy 
and/or hysterectomy) was 20.8 % as compared to 8 % in our population94. This probably 
reflects different therapeutic traditions in Norway and USA, and we believe that our 
cohort is more representative for the general population regarding symptom burden and 
menopausal age. The size, the representativity, the frequency of recordings, and the low 
number of drop-outs make the Cohort a unique database for studying women’s health 
during the menopausal transition.
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Discussion of the results.
Knowledge and attitudes towards HT among Norwegian GPs. 
Indications and contraindications for HT. Relief of symptoms. 
Relief of bothering hot flushes/night sweats was the overwhelming indication for 
HT in our survey, although other indications obviously also played an important role. The 
preventive effect of HT on osteoporosis and low-energy fractures was the second most 
important indication, and is discussed below. We found that mood variations and 
bothersome vaginal dryness also were important indications, along with reduced libido. 
Aging of the skin was not regarded important as an indication by the majority, contrary to 
the belief in beneficial effect. The most important finding was that along with the main 
indication relief of bothersome VMS, other not established indications like effect on 
mood swings and libido obviously were important for the doctors. The GPs have a 
clinical competence and work close to their patients, and assumed amelioration of such
symptoms might tip the weight in the pro et contra discussion with the patient and lead to 
prescription. Few of the independent variables seemed to play a role when assessing the 
indications, with the exception that GPs who did not regard treatment as medicalisation 
placed greater emphasis on the indication “mood swings”. Thus, the general attitude to 
HT had some influence. 
Regarding contra-indications, breast cancer in the medical history or among first 
grade relatives was the most important, but also CVD and thrombo-embolic disease 
among close relatives were regarded as important contra-indications. These findings are 
in line with results in studies among Scandinavian gynecologists after WHI183, and 
indicate that the GP’s were fairly well updated on the risks and side effects of the 
treatment. The female doctors placed greater emphasis on “breast cancer in the immediate 
family” as a contraindication than their male colleagues. This effect indicate that the 
female GPs were more aware of the association between HT use and breast cancer, which 
was documented in the British MMS and the Norwegian Women and Cancer study in 
2003-2004123,124.
The attitude to HT among Norwegian GPs was examined in a survey prior to a 
consensus conference on HT arranged in Norway in 1990184. A second survey was carried 
out after the conference to evaluate the effect of an information campaign among 
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Norwegian GPs185. In general, a restrained attitude towards prescription of oestrogen was 
found. The intervention (an information package with recommendations from the 
consensus conference and information about the treatment) did not significantly alter the 
willingness to prescribe. However, the doctors had more patients on HT in 1992 than in 
1990. From 1993 onwards, several surveys were performed in Norway and the other 
Scandinavian countries to explore the attitudes and use of HT among gynecologists112,186-
188. However, no GPs were included in these studies.
There are some differences between the findings in the 1990-92 GP survey and 
our results, although all taken together they are remarkably consistent. In our survey, the 
increased risk of breast cancer was very well known among the GPs. This was not asked 
for in the 1992 GP study. Smoking and a family history of cardiovascular disease reduced 
the willingness to prescribe HT in 1992. In 2004, the majority of GPs clearly disagreed 
with the statement that HT protects against cardiac infarction. Moreover, symptomatic 
cardiovascular disease and thromboembolic disease among close relatives were regarded 
as contraindications. Thus, it seems that GPs both in 1992 (contrary to the current 
evidence) as well as 12 years later (when the evidence had changed) regarded that HT 
could be a risk factor for CVD. 
Assessment of effects of HT related to sex life and feminity 
In our study, other benefits of HT were rather controversial, and the opinions
among the GPs were diverging as to many of the effects we asked them about.
Approvement of the indication “bothered by vaginal discomfort” was a specific question, 
and the statement “HT improves sex life” intended to catch a broader aspect of the sex 
life, such as effect on libido (which was also asked for as a possible indication). More 
than 2/3 of the doctors agreed to the statement that HT improves sex life. This may be an 
important element in a pro- and contra discussion with the patient, not to say when a 
female GP considers using the treatment for herself, or when a male GP discusses the 
topic with his partner. A number of publications support this189-192. However, the studies 
are small and the population usually selected, so the quality of this evidence can be 
questioned. Systemic and local application of estrogen clearly has beneficial effect on
relieving dyspareunia, likely because of its impact on vulvovaginal atrophy193. Many 
other factors seem more important for women when it comes to evaluate causes of 
impaired sexual satisfaction190. The effect of systemic HT on libido or other aspects of 
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sexual desire has not been demonstrated194. A literature review found beneficial effect on 
sexual desire and satisfaction when androgens was added195.
Almost half of the GPs were of the view that HT counteracts aging of the skin, 
and this is probably also an important factor for the women themselves. Similar views 
have been found in surveys among gynaecologists196.  For many women in the target 
group for HT, external signs of aging are undesirable. It is particularly important to avoid 
wrinkles and sagging skin. 
Other aspects of treatment regarding sense of well-being and quality of life 
seemed less important. The statement that HT makes women more attractive had few 
supporters. 
In sum, many of the GPs had belief in beneficial effects of HT connected to the 
“feminine aspect” which has weak scientific evidence in the literature.
Preventive effects of HT 
As mentioned above, the preventive effect on osteoporosis and low energy 
fractures is well known and was regarded as a reason to prescribe HT. However, the 
wording of the question was not specified in order to investigate if the doctors still had 
HT as a first choice for prevention of low energy fractures. 
The majority of GPs had no confidence in the preventive effect against CVD, or 
for other preventive effects of HT. The doctors who were negative to the statement that 
HT implies medicalisation were most in favor of preventive effects. Also, male doctors 
were significantly more positive to the statement that HT could prevent heart infarction. 
The fact that a third of the doctors were uncertain whether HT prevents cardiac infarction 
or believed that it does, may indicate prevailing uncertainty and confusion about the 
effects and risk associated with HT. There was higher support for the statement that HT 
could prevent Alzheimer’s dementia. When the study was performed, positive results 
regarding HT effect on cognitive function had been published115,197,198, but these studies 
were small. A meta-analysis published in 2001 found a decreased risk of dementia among 
HT users in observational studies, but found that most studies had important 
methodological limitations and called for further, specific research199. The Alzheimer part 
of the WHI study published in 2003200 and the cognitive function part of HERS201 from 
2002 found a negative effect of HT on cognitive function. Later, a study from Denmark 
reported positive effect of HT on cognitive function among younger women202, and a 
“timing hypothesis” for a positive preventive effect if HT was started early has been 
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discussed. However,  a recent literature review conclude that HT have a negative effect 
on cognitive function and do not prevent dementia203. The 2012 US Preventive Task 
Force Recommendations, the latest Cochrane report and also the 2012 NAMS statements
conclude that HT should not be used to prevent or treat cognitive loss in postmenopausal 
women136,145,204.
Treatment duration 
An important change in the recommendations had to do with follow-up and 
reconsidering the indication for treatment, and the duration of treatment. Treatment 
should be revised annually, and the benefits and risks for the individual woman should be 
discussed. Discontinuation attempts should be carried out. After 3-5 years a major 
revision should be done and discontinuation should be tried, since treatment longer than 
five years were connected to higher risk for breast cancer123.
In our study, one in every four doctor did not have a general rule concerning the 
duration of treatment, so the adherence to the control and duration of treatment 
recommendation was modest. Among those who had a rule, only a minority would 
administer treatment for less than a year.  Female doctors had higher odds for having a
general rule for duration of treatment compared to male GPs, thus indicating that female 
GPs were more concerned about side effects and risks of the treatment. 
The medicalisation issue 
In our study, almost 1/3 of the GPs agreed to the statement that HT implies an 
undesirable medicalisation of a natural life phase of women, while 44 % disagreed. Since 
the medicalisation debate had taken place mainly in the 1970s, and to a large extent was 
initiated by a feminist critique of the treatment, we assumed that the attitude to this
statement would follow age and gender. However, our study demonstrated that this was 
not the case. Of the independent variables, none predicted the attitude to the 
medicalisation statement. We must therefore assume that the position regarding the 
medicalisation question follows more general political or cultural attitudes. Our survey 
does not contain data to confirm this, or other hypotheses. The question is of interest, 
since we found that the attitude towards medicalisation was significantly associated with 
the advice given in the clinical examples (cases), and also was associated with statements 
about effects: Those who disagreed to the medicalisation statement, were more positive to 
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statements about preventive effects of HT and also put emphasis on positive effects, e.g.
effects on mood swings. 
To our knowledge, similar questions have not been put forward in other surveys 
regarding doctors’ attitudes and views on HT. Therefore, it is not possible to compare to 
other groups of doctors, or with doctors in other regions of the world. In Norway, the 
discussion among GPs about medicalisation was rather extensive during the 1970s and 
prevailed in other arenas of medicine during the 1980s and 1990s, e.g. treatment of 
hypertension and prevention of CVD19.
Liberal prescription attitudes and several assumed effects of HT were prevalent 
among the gynecologists during the 1990s. In a survey among Scandinavian
gynecologists published in 2001, 42 % offered HT routinely to all women provided there 
were no contraindications186. Reduced libido and mood alterations were regarded as 
important indications for prescribing HT, along with hot flushes and osteoporosis 
prophylaxis. Although the attitudes to prescription among gynecologists became more 
restrictive after 2002205, many of the assumed effects seem to prevail. In a recent study 
from Germany, prevention of osteoporosis, prevention of cognitive disorders, bleeding 
disorders, reduction of libido, incontinence and atrophic vaginitis leading to dyspareunia 
still were important indications, although relief of vasomotor symptoms was the most 
important indication196.
Perception of role  
As expected, female doctors discuss HT more often than their male colleagues.  
We found that about one third of the GPs regarded that they usually took the initiative to 
stop treatment, while fewer GPs took the initiative to start. The fact that less than half of 
the doctors regarded that it was usually the woman who took the initiative to start, and 
only one fourth that the woman took the initiative to stop treatment may indicate that the 
majority of doctors regarded that they were active in giving advice. The finding may 
reflect a traditional perception of role among many GPs to be active and take decisions, 
assuming that the medical knowledge shall enlighten the patient. The perception of role 
was associated with the standing towards the medicalisation question, as the doctors who 
disagreed to the statement were much more apt to give advice to start treatment, and those 
who agreed were much more apt to discontinue treatment.  It was, however, almost half 
of the doctors who regarded that it was the patient just as often as the doctor who took the 
initiative to start or stop HT, indicating that this is a field of medicine where shared 
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decision making takes place to a great extent. Not surprisingly, the active “start HT” role 
described among gynecologists during the 90s was rare among GPs in our survey. 
To treat or not to treat – that is the question. Heuristics and biases. 
Giving advice in favor of or against HT is a matter of weighing the advantages 
(positive effects) against the disadvantages (side-effects or risk) for the individual patient. 
After WHI, the scientific basis of efficacy and risk is better documented, and the 
recommendations clearly state that HT should only be prescribed to women with 
bothersome vasomotor symptoms with a negative impact on the woman’s quality of 
life128. We might then assume that the doctors would be fairly unanimous in the advice 
they give. However, the division of GPs into two “camps” as regards their views on 
hormone therapy reveals a striking divergence. 
The likelihood of recommending therapy was four times higher among the doctors 
who did not agree that HT implied medicalisation compared with those who agreed with 
the statement. There was no correlation with other background variables, view of 
indications or contraindications or perception of risk associated with therapy. A number 
of those who would neither recommend nor advise against therapy (n = 129), commented 
that they would discuss the pros and cons and allow the patient to decide herself. 
Thus, the doctor’s general attitude – “positive” or “negative” – to HT measured by 
the medicalisation question played an important role while the perception of risk inherent 
in the therapy played a lesser role when the decision to advice treatment or not was taken.
Such a positive or negative attitude may represent what is termed “affect heuristics»158 in 
psychological research. Affect heuristics link feelings to alternative choices, and help us 
to make speedy decisions that are consistent with our own values and intuitive 
preferences. By the same token they can also result in incorrect practice in that such 
patterns survive attempts to change them by means of scientific or logical reasoning. In 
fact, there is a vast literature applying the heuristics concept in other disciplines, such as 
economy and psychology206. Other examples of important heuristics are recognition 
heuristics and availability heuristics. Recognition heuristics is typically used in medicine 
when a doctor diagnoses a disease based on recognition of a typical pattern he or she has 
seen before, such as herpes zoster or Parkinson’s disease. Availability heuristics is used 
when the person limits the sources of information to what he or she already have access to
or know, sorting out the other and more complicated or less available sources of 
information. Finally, the optimism bias is working when we take into account the positive 
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elements favoring a decision we want to achieve or the outcome we prefer, leaving out 
the “bad news”.  Heuristics are significant when people make decisions in complex areas 
with many elements of information, such as doctors do when they make up their mind to 
treat or not. Although there is little discussion of the importance of this concept in 
medicine, these factors should be taken into consideration when new evidence-based 
guidelines are adopted or implemented in order to change practice.
All taken together, the GPs were fairly well updated regarding the main effects, 
indications and contra-indications. A proportion of the male doctors seemed less well 
updated regarding the results from WHI. At the same time, many assumed effects of HT 
that is less well documented, like preventing skin aging and enhancing sex life, also seem 
to play a role in the picture of reasons to use HT. Given the uncertain documentation and 
unclear communication of some of the effects or that they have not been grasped by the 
target group, it may appear that HT’s assumed positive and non-specific significance for 
“the female aspect” is assigned greater importance in the clinical decision-making 
process.
Do the female GPs use HT themselves? 
In our survey, 14 out of 17 (82 %) menopausal or post-menopausal female GPs 
stated that they used or had used HT in connection with menopause. Because a relatively 
small proportion of GPs in our survey are menopausal or post-menopausal women, only a 
few have answered these questions, and the figures must be interpreted with caution.
However, the result is in line with other studies finding that HT use among doctors is far 
more prevalent than in the ordinary population183. No change in HT use was observed 
among gynaecologists between 1997 and October 2002 (after WHI)205. In comparison, 
only about a quarter of Norwegian women aged 50–69 in 2004 stated that they used or 
had used HT. A  recent study from Germany showed a remarkably high proportion of 
willingness to use HT among female doctors (96.5 %) and male doctors who would 
prescribe HT for their partners (98 %)196. For some of these indications, the willingness to 
use it oneself was greater than the willingness to prescribe it for patients. In an Italian 
study from 2003, the willingness to use HT was markedly higher among gynecologists 
(56-59 %) than among GPs (30-31 %) or oncologists (16-30 %), and few doctors or 
doctor’s wives stopped using HT after the WHI trials207.
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The finding deserves a reflection: Why do doctors state that they have become
more restrictive when prescribing HT, at the same time continuing to use it just as before?
Several important factors stand out as possible explanations for the difference in 
consumption pattern. Doctors have ready access to drugs and are familiar with their use, 
and have lower thresholds against use of drugs than others208-210. Furthermore, doctors
may judge the risk for themselves associated with HT as small compared with the benefit.
Indeed, for persons without additional, underlying risks, such as previous thrombosis or 
breast cancer, the absolute risk (and risk increase) is low. Additionally, it takes some 
time for knowledge to replace attitudes and practice211. During at least one or two 
decades, HT has been judged beneficial and harmless. Both the “optimism bias” and the 
availability heuristic will lead to preservation of a practice of use and self-prescription.
Included in these benefits are effects linked to sexuality and the “feminine aspect” which 
many doctors have confidence in. These aspects are important also for the doctors. Our 
survey does not say anything about the significance of these or other possible 
explanations.
Menopausal symptoms in the HWC study 
An important finding in the HWC study was that the prevalence of frequent and 
bothering vasomotor symptoms and vaginal dryness were considerably lower than 
reported in other surveys among Western, Caucasian women53-55. We found a peak 
prevalence of daily hot flushes in the 53-54 age group, when 22 % reported daily hot 
flushes, 17 % weekly, and 21 % was considerably or very much bothered by them. 41 % 
was not bothered by hot flushes in this most affected age group. When comparing with 
the North American Swan study73 (cross-sectional prevalence, 5 different ethnic groups, 
16,075 women), the peak prevalence of combined VMS (hot flushes and/or night sweats)
in the same age group (52-55 years) was 46.6 % (reported symptoms in the last two 
weeks). In this study, the highest prevalence was found among Afro-Americans and the 
lowest among the Japanese and Chinese ethnic groups.
In European studies, the prevalence of symptoms is even higher (Table 1, Table 2). Our 
figures of bothersome hot flushes are, however, largely in line with findings in the 
Norwegian Menopause Project from the 1980s57.
Our results correspond to previous findings as to the time from FMP to peak 
prevalence of symptoms.  In a recent meta-analysis, Politi found that symptoms peak 1-2
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years after FMP, when approximately half of the women experience bothersome 
symptoms55.
Also, the prevalence of vaginal dryness is lower in our study compared to others.
The number of studies reporting vaginal dryness is lower than for VMS and most studies 
report symptom prevalence in the range of 20-50 %, highest in late 
postmenopause44,53,67,68.
So – does the lower prevalence of VMS and vaginal dryness in the HWC mean
that Norwegian women have less symptoms compared to other Western, Caucasian 
women? The strength in our study is the representativity and the long observation time, 
and the low attrition rate in the cohort. The design of the study seems to play a role. When 
comparing with other population-based longitudinal studies, such as SWAN73 or the 
Australian MWMHP44, the differences are smaller. In cross-sectional studies, the 
prevalence is usually higher than in longitudinal studies. In our study, women with 
surgically induced menopause were excluded, thus contributing to somewhat lower 
symptom prevalence’s in HWC. Inclusion of these women raised the peak prevalence of 
daily hot flushes 1-2 % across the age groups.
It is also worth noting that almost one out of three of our respondents never or 
almost never experienced any hot flushes or night sweats during the menopausal 
transition. Since our observation period is up to ages 53-57, we expect that this proportion 
may become lower during prolonged follow up. 
In some prospective studies, attitudes to menopause (positive or negative) are
associated with prevalence of symptoms. Women with negative attitudes before 
menopause tend to report higher frequency of symptoms when reaching the 
menopause212,213. It is possible that the women in HWC (and Norwegian women as such) 
have more positive attitudes to menopause than other Western women. In Norway, the 
percentage of women working outside the home is among the highest in world214,215 .
Participation in work may contribute to more positive self-evaluation during the 
menopause. We have, however, no data to support this hypothesis. Other cultural or 
socioeconomic differences may contribute to the observed differences in reported
symptoms, such as differences in therapy traditions, access to specialized care and 
perception of the role as an elderly woman in the society. The degree of medicalisation of 
the menopause, that is the extent to which menopause is regarded as a medical condition,
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may vary also between western-oriented countries, and contribute to the differences 
found.
Following the individual women across the age span also revealed a great variety 
in frequency and degree of bothering symptoms. Some women reported an early onset of 
symptoms, but a rapid decrease, others had no decrease or a two-puckled curve, and still
others had late onset or very low frequency of symptoms. The youngest woman started 
with daily HF at age 41, and the oldest at an age of 57 years. The great variation in 
symptom debut, the duration of symptoms and the variation in intensity across the 
transition is interesting and may also be of clinical interest, since is shows the great span 
of normality as such. 
Although the symptom burden in the HWC seems lower than in comparable 
populations, it is important to keep in mind that a minority of women reported very 
frequent and bothersome symptoms over a long time span. Twenty-eight women (1 % of 
the Cohort) reported daily hot flushes in six or seven questionnaires, indicating more than 
10 years of bothersome symptoms. 
All taken together, we assume that our study shows that the prevalence of 
bothering symptoms among Norwegian women is among the lowest reported up to now 
among Western, Caucasian women.
Factors associated with frequency of symptoms. 
Of the independent variables recorded, daily smoking was the life style factor 
which was most significantly associated with the intensity of symptoms. Odds for 
reporting daily hot flushes was 1.5 (1.2 - 1.9) for daily smokers vs. non-smokers. The 
finding that daily smoking was associated with more frequent hot flushes, confirms 
results from other surveys72,73,216. Our study also showed that daily smoking was 
associated with lower age at FMP. The effect of smoking on symptom prevalence and
FMP may reflect a biological anti-estrogenic mechanism, as mentioned earlier77. We did 
not find that degree of physical activity or overweight (BMI) before the menopausal 
transition was associated with increased or less vasomotor symptoms, although women 
with BMI > 25 kg/m2 had a slight, non-significant lower odds for reporting daily hot 
flushes (OR=0.8, CI 0.68-1.01, p=0.064). The finding that hard physical activity during 
the menopausal transition was associated with more symptoms may reflect that women 
with more symptoms become more physically active in this period due to a belief that 
physical exercise may in itself reduce vasomotor symptoms82.
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Our study confirms earlier findings that educational level is associated with 
symptom reporting71,87. Women living single had higher odds for daily or weekly hot 
flushes, compared with women living in partnership or marriage. Self-reported health at 
baseline, family income or age at menarche recorded at baseline had no significant 
influence on symptom reporting. The same associations were found for women with 
fewer symptoms (weekly and/or monthly symptoms) compared to women without 
symptoms, except for educational level where no association was found. The association 
between symptoms and educational level is somewhat difficult to explain, since we 
controlled for other factors, such as income, smoking or other life style factors. It is 
possible that the association has to do with higher self-confidence and contention with 
life, and higher levels of employment outside the household, which has been found to be
associated with lower reporting of symptoms72.
Self-rated health and association with symptoms. 
In the Cohort, overwhelming and stable proportions reported that their present 
health status was good or very good. From 2002 (Wave 3) onwards, only small, not 
significant variations in self-rated health took place. There was no indication that 
different values of self-rated health at baseline predicted later vasomotor symptoms. 
However, the analysis indicated a correlation between this perceived health status and the 
burden of vasomotor symptoms in the separate waves. However, the size of the effect was
modest. Other studies have demonstrated that most women cope very well with the 
symptoms of menopause, and that there are many aspects of life that have much more 
influence on psychological well-being in the midlife years, such as new roles (being 
grandmother), becoming more experienced and competent, being better to stand up for 
oneself, and other factors217-219.
We conclude that frequent hot flushes were associated with higher prevalence of 
reporting self-rated health as “bad” or “not so good”. The effect was not sufficient,
however, to cause changes in the cohort as a whole.
Age at menopause and factors associated with this age. 
Excluding users of hormonal IUD, mean (with 95% confidence interval, CI) and 
median age at FMP in the Cohort were 51.1 (50.9 to 51.3) and 51 years, respectively. 
Daily smoking at baseline or later was associated with lower menopausal age. In NMP, a 
mean age of menopause of 52.9 years was found10, but the final sample used was small 
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and the representativity of the sample is questionable. In addition, a 6-months amenorrhea
criterion was used. However, our results are largely in line with other studies103,104. In a 
recently published European cross-sectional study, higher ages for FMP and less 
influence of smoking were reported102, and the question was raised whether menopausal 
age in Europe is increasing. The Finnish study104 is, like ours, a representative, 
community based cohort, and this may explain the similarity in our results. A cross-
sectional design will be more vulnerable to recall bias than a longitudinal design.  In 
conclusion, our data does not support the hypothesis that age at menopause in Europe is 
increasing.
HT use in the cohort.  
We detected a sharp, significant decrease in the frequency of new HT users 
between 2002 and 2004, despite the increasing prevalence of vasomotor symptoms in 
women. This was obviously explained by the publication of the WHI results and the 
following media focus on “dangerous hormones”, which were picked up by the women 
themselves220. After 2002 (Wave 3), the prevalence of HT users in the HWC was stable 
throughout the observation period, although the women passed through the menopausal 
transition and experienced increasingly bothersome symptoms. Obviously, many women 
preferred to pass through the menopausal transition without HT, despite their bothersome 
symptoms. Also, more narrow indications for HT use were followed by the women and 
their doctors21,221.
The prevalence of HT use corresponded with the findings of a Norwegian cross-
sectional study from 2005, which reported 10.1 % current use while 31.3 % of women 
had used HT at some point167. The prevalence of current HT use was lower than that 
reported by two Swedish surveys where the prevalence in the corresponding age group 
was 22.9-25.3 %222,223, and also in a 2005 US study, which reported 20 % current and 50
% ever HT use among postmenopausal women224. These observational studies were 
cross-sectional rather than longitudinal like ours, which limited any comparisons. 
However, our results support findings from the early 1990s, which showed that 
Norwegian women were generally reluctant to use HT184,225.
Following secondary analyses of the WHI data, some authors have argued in favor 
of a “window of opportunity” for initiating HT by suggesting that HT may actually have a 
cardio protective effect if it is started within 5-7 years after menopause223,226. Our figures 
do not indicate that the women or their doctors have confidence in these arguments. On 
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the contrary, there is no evidence for increased prescription of HT during the last years in 
the cohort. Instead, the incidence seems to be falling.
On the other hand – since the women reported more symptoms during this period, 
there is a risk for under-treatment:  perhaps many women suffered reduced quality of life
in this period because their bothersome symptoms were not adequately treated?  In our 
study, self-rated health was used as a proxy for self-assessed quality of life. The 
proportion of women reporting self-rated health “bad” or “not so good” in the different 
waves was stable from 2002 onwards when the prevalence of daily hot flushes began to 
rise (Paper IV, Table 1, Fig 1). Our study design does not allow inference as to whether 
individual women have been under-treated, but the stable distribution of self-rated health 
categories after 2002 does not indicate systematic under-treatment in the cohort. In other 
words, we do not have reasons to believe that the low prevalence of use have led to 
reduced quality of life in this age group.
We had a long follow-up period and a significant proportion (12.7%) of the HWC 
still used HT when the study was completed. Thus, the proportion of long-term users and 
the mean duration of treatment are probably longer than those reported here. In another 
longitudinal Norwegian study, the mean duration of HT use among current users was 6.3 
years in 2005, but the proportion of long-term users was much higher (60 %) compared 
with that of long-term users in our study (27 %)167.
On average, HT was initiated at FMP, although some started as many as 10-12
years before FMP. Start of VMS at an early age might have been the main reason for 
initiation of HT before menopause. Another possible explanation is that bleeding 
disturbances before FMP may have been regarded as an indication for prescribing HT22. It 
is also worth noting that a large proportion of the women started HT use up to four years 
after menopause, which reflected the wide ranges in the symptom prevalence and 
duration, as well as other possible reasons for using HT, such as bleeding disturbances.
The prevalence of hot flushes (daily or weekly/monthly) was the main factor 
associated with HT use. This association was strongest for the long-term users and for 
women who started pre- or perimenopausal. We suggest that this observation indicates 
that treatment of vasomotor symptoms was the main reason for using HT, while other 
reasons had less important roles. In the cross-sectional analysis in Wave 7 (Paper IV,
Table 4), this association was weaker and not significant. We suppose that in this wave, 
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the women had used HT for a longer period and that the effect of the treatment wiped out 
the difference between users and no-users.
The odds of using HT were increased by the age of women at baseline. This may 
have been because a proportion of the younger women had not yet reached menopause at 
the end of the observation period, although it may also reflect an increasing skepticism
about HT among the younger women. The age effect was less pronounced over time, and 
was not significant in the last wave. The finding indicates that the main factor for use was 
the increase in symptoms around and after FMP.
No associations were found between HT use, education, or income, which 
contrasts with the findings of surveys from the 1980s and 1990s227,228. However, our 
findings are largely in agreement with more recent studies167,229. This may reflect a shift 
in medical practice from general prevention towards targeted relief of troublesome 
symptoms. However, the prevalence of HT use among female GPs found in a Norwegian 
survey may reflect only minor changes in doctors’ attitudes to HT use230.
The association between HT use and smoking was somewhat paradoxical because 
the increased risk of thromboembolic disease associated with HT use may be regarded as 
a relative contraindication for HT use among smokers. After analyzing the symptom 
prevalence and the factors that predicted symptoms in the HWC, we found a positive 
association between symptom prevalence and daily smoking231. Thus, the increased 
burden of vasomotor menopausal symptoms among smoking women was probably more 
important than the increased risk of thrombosis in smokers. 
We found a positive association between HT use and the degree of urbanization.  
An explanation might be easier access to gynecologists in the cities, but other factors 
related to local cultures and attitudes are also possible.
Reappearance of symptoms after discontinuation of HT  
We found that menopausal symptoms often reappeared after treatment cessation, 
which is in line with other studies223,232. Reappearance of symptoms is biologically 
plausible and is also supported by data showing that the duration of the menopausal 
transition is actually longer than previously reported55. Hormone therapy relieves the 
symptoms and is not directed at the basic mechanisms responsible for the vasomotor 
symptoms. Many women restart HT after discontinuation attempts232-234. Recent figures 
from Sweden showed that 87 % experienced symptom reappearance after HT 
discontinuation, irrespective of the treatment duration235. Our finding indicate that when 
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HT is taken to relieve symptoms, one must expect that it is necessary to use it over 
several years, and may be longer than the maximum treatment period of 3-5 years that is 
advised in the guidelines.
The majority of former HT users in our study reported side effects, or the fear of 
side effects, as the most important reasons for stopping treatment. This indicates that 
women were aware of the possible side effects such as an increased risk of breast cancer. 
Our GP study also indicated that the doctors were aware of this risk and the majority of 
them complied with the guidelines, which recommend treatments shorter than five 
years230. However, few have asked why women continue to use HT. In a study from a
gynecological practice in London published in 2006, only 3 % of women who used long-
term HT implants wanted to discontinue their treatment236. Depression and loss of energy 
and/or libido were their main concerns for HT discontinuation while few feared relapse of 
vasomotor symptoms.
Concluding remarks 
An important finding in the HWC study was that the prevalence of bothersome 
symptoms in the cohort was lower than previously reported in other surveys in 
comparable populations. One third of the women experienced bothersome symptoms 
during the menopausal transition and early postmenopause. However, only a minority 
suffered from these symptoms for several years. Also, the prevalence of HT use was 
lower than reported from our neighborhood countries, and our data do not support that the 
relatively low prevalence of HT use impaired the quality of life among the women in the 
cohort. 
Thus, we may conclude that on average, the women in the Cohort were not very 
bothered, and many women preferred to pass through the menopausal transition and early 
postmenopause without use of HT despite frequent VMS. On this background, we also 
conclude that systematic under-treatment of women was not found in our material.
The finding that bothersome hot flushes was the factor most consistently 
associated with HT use indicates that this was the most important indication for HT, 
confirming that the majority of  women and prescribing doctors use HT to alleviate 
symptoms. Other indications, e.g. prevention of chronic disorders played a smaller role. 
This finding is also in accordance with the GP study. The mean duration of treatment, 
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reported by the women themselves was in line with the recommendations, although a 
proportion of women obviously had used HT for a longer period. Among the GPs the 
adherence to the recommended maximum treatment duration was less obvious. This 
should not be a surprise, since up to 8 percent of the women reported hot flushes for 8 
years or more, and most women experienced reappearance of vasomotor symptoms after 
HT cessation.  
In line with other findings, we found that symptoms reappeared in most women 
after HT cessation. Further research is needed to clarify in more detail how long the
treatment must be for symptoms to ware off. 
When analyzing factors influencing prevalence of bothersome symptoms, daily 
smoking was a significant risk factor, while most of the other background and health 
factors had little or no effect. This finding should encourage women to quit smoking.
A remarkable finding in the GP study was that the advices given in the case 
histories were quite diverging. The result indicates that the attitude of GPs to HT, given in 
the survey as agreement with the statement that HT implies an undesirable medicalisation 
of a natural life phase in women, was a key explanatory variable for recommending
treatment when presented clinical examples. The same factor was associated with how 
active the doctor was in starting or stopping treatment, as was also gender and age.
However, differences in other background variables, such as perception of risk or effects
of the therapy showed no corresponding correlation. This finding is of interest, since 
several attempts have been made to encourage doctors to change practice in fields of 
medicine where new evidence have emerged, and there is a need for change. 
Traditionally, guidelines with scientific based arguments with or without treatment 
algorithms are used. May be it is more efficient to explore tools aimed at changing
attitudes and affect heuristics? This is a field that demands further research.
Finally, the high prevalence of HT use among female GPs found in our study 
indicates that the doctors weigh risks and benefits differently from what their patients do, 
and also differently from what they do when they advise their patients. The finding is in 
line with other surveys. However, the reason for this striking difference regarding HT use
has to my knowledge not been studied further, and represents another interesting issue 
that needs to be explored.
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Kjære deltaker i kvinneprosjektet i Helseundersøkelsen i Hordaland  
Vi henvender oss igjen til deg som en av de to tusen kvinnene som sa ja til tilbudet om å 
delta i denne undersøkelsen, og som har bidratt til dette viktige forskningsprosjektet 
gjennom 10 år. Spørreskjemarundene har hatt en formidabel oppslutning, som har vakt 
internasjonal oppsikt, nå sist på en kongress i USA der innlegget om undersøkelsen vår 
ble kåret til et av de 50 beste blant mer enn 1000 innlegg fra 2500 deltakere! 
 Det er nå tid for ny runde med spørreskjema. På grunnlag av svarene får vi ny kunnskap 
om vanlige kvinneplager. Vi håper også at kunnskapen senere kan benyttes for å 
forebygge og behandle plagene. Både Norges forskningsråd og Helse Vest støtter 
undersøkelsen med penger etter å ha vurdert den vitenskapelige verdien som stor. 
Vi håper derfor at du også denne gangen vil fylle ut skjemaet og sende det til oss innen 
noen få dager i den ferdig frankerte konvolutten. Spørreskjemaet er merket med et 
4-sifret referansenummer for at vi enkelt skal registrere svarene dine rett. Data blir 
etterpå lagret og bearbeidet anonymt. Vi trenger referansenummeret bare for å kunne vite 
hvem som har svart, og bare en person (som har taushetsplikt) skal arbeide med skjema 
der navnet viser. Forskerne arbeider bare med anonyme datafiler.  Dersom du ønsker det, 
kan du klippe bort navnefeltet øverst på svararket.
De fleste av spørsmålene svarte du også på sist. Mye av verdien av denne undersøkelsen 
ligger nettopp i å følge utviklingen hos de samme personene i mange år. Den observante 
deltaker vil se at vi har et par nye spørsmål, blant annet om vekten din som ung! Det er 
fordi ny utenlandsk forskning har vist at ungdomsvekten kan ha betydning for senere 
symptomer, og vi ønsker å sjekke om dette stemmer også i Norge. Vi spør denne gangen 
også om litt flere detaljer når det gjelder hormonbehandling. 
På baksiden viser vi noen glimt av resultatene fra forrige runde. 
Vi er takknemlige for at du hjelper oss, og at du er med videre. Noen av dere har flyttet 
ut av Hordaland. Vi vil gjerne ha også dere med videre, fordi dere bodde her da 
undersøkelsen startet. Vi regner med at det nå går 2 år før neste skjemarunde. I 
Hordaland er det like mange som bruker nynorsk som bokmål. Denne gangen er det 
bokmålsbrukerne som får skjema i sin målform! 
Vennlig hilsen 
Steinar Hunskår 
Professor
Glimt fra resultatene i forrige runde 
Hormoner og hormonbehandling 
De fleste deltakerne i studien var ved forrige spørreskjema fra 48-53 år gamle. Det betyr 
at de fleste var i overgangsalderen, noen med lite eller ingen plager, men noen med 
daglige hetetokter og nattesvette. Nedgang i hormonproduksjonen er antatt å ha 
sammenheng med en rekke symptomer i tillegg til de man vanligvis forbinder med 
overgangsalderen. Eksempler er urinveisinfeksjoner, migrene, nedsatt bentetthet og 
livmorfremfall. Noen kvinner bruker hormonbehandling for å lette plagene fra 
overgangsalderen. Derfor er det viktig for oss å få kartlagt legemiddelbruken. 
Figuren viser svarfordelingen i forrige runde på spørsmålet Bruker du hormoner mot 
plager i overgangsalderen?
Vi er spent på om det er endringer etter to år! 
Alternativ behandling 
Vi vet at mange personer bruker alternative behandlere i tillegg til sin vanlige lege. Det 
synes vi er interessant å få kartlagt. Gjennom undersøkelsen kan vi se hvilke plager man 
går til lege for og får medisiner mot, og hvilke alternative medisiner man bruker 
istedenfor, eller i tillegg. Dessuten har vi flere ganger spurt om dere har vært til alternativ 
behandler siste året. Det har mange av dere vært! En firedel av dere svarte positivt på 
spørsmålet forrige gang, og her er fordelingen over hvem denne firedelen har hatt kontakt 
med: 
Aldri brukt (73%)
Brukt før (14%)
Bruker nå (13%)
0 10 20 30 40 50
Andre
Magnetfelt
Kinesolog
Fotsoneterapeut
Healer
Homeopat
Aromaterapeut
Akupunktør
Dato for utfylling:____/____-20____  Hva er alderen din nå? ____ år
Hvordan er helsen din nå? (Sett bare ett kryss)
 Dårlig Ikke helt god God Svært god
    
Har du vært hos lege eller ligget på                                JA       NEI  
sykehus det siste året?................................................
Dersom ja, gi stikkord for grunnene (diagnose, problem) 
1. grunn  _________________________________________
2. grunn _________________________________________
3. grunn _________________________________________
4. grunn _________________________________________
 
 
JA NEI
Har du vært hos "alternativ" behandler siste året  
 Dersom ja, har du vært hos:
 Akupunktør Homeopat
 Fotsoneterapeut Aromaterapeut
 Kinesolog Healer
 Urtemedisiner Magnetfeltterapeut
 Andre; spesifiser
 
Hvordan har den fysiske aktiviteten din i fritiden vært det siste året? 
Tenk deg et gjennomsnitt pr uke når du ser hele året under ett. 
Arbeidsvei blir regnet som fritid. Svar på begge spørsmålene.
 Timer pr uke
 Ingen Under 1 1-2 3 og mer
Lett aktivitet
(ikke svett/andpusten)    
Hard fysisk aktivitet
(svett/andpusten)    
Hva er vekten din nå?  _____kg   Hva er høyden din nå?______cm
Hva var vekten din ved ca 20-års alder? ______kg
 
JA NEITrener du bekkenbunnen (knipøvinger)  
en gang i uken eller oftere?...........................................
Røyker du sigaretter daglig?........................................  
  Dersom ja, hvor mange sigaretter:  _________
   
   
 
 JA NEI
Har du regelmessig menstruasjon? .......................   
Når hadde du siste menstruasjon?
                                          måned:  ____________  år: ____  
Det er stor variasjon i hvilke plager overgangsalderen gir og når 
den kommer hos hver enkelt. Har du plager som kan settes i 
sammenheng med overgangsalderen? Og hvor plaget er du? Svar 
med 1 kryss for hvor ofte du har ett eller flere av de 3 symptomene 
nedenfor, og sett 1 kryss for hvor plaget du er.
SYMPTOM HVOR OFTE OPPLEVER DU DETTE?
 Aldri/nesten aldri Månedlig Hver uke Daglig
Hetetokter    
Svette/nattesvette    
Tørr/sår skjede    
SYMPTOM  HVOR PLAGET ER DU?
 Ikke Litt En god del Mye
Hetetokter    
Svette/nattesvette    
Tørr/sår skjede    
Bruker du hormoner mot plager i overgangsalderen?
 JA   Nei, aldri brukt     Brukt før; hvor lenge:___år og ___mnd
Hva var alderen din da du startet: ___år
Hvorfor sluttet du?
 Opplevde bivirkninger         Ikke lenger behov
 Engstelig for bivirkninger    Annet: _________________
Hvilke(n) prevensjonsmetode(r) bruker du? (Flere kryss mulig).
  Minipille   P-sprøyte
  P-piller   Pessar 
  Hormonspiral   Sæddrepende krem
  P-plaster på huden   P-stav under huden
  Vanlig spiral   Jeg er sterilisert
  Kondom hos partner   Partner er sterilisert
  Trenger ikke prevensjon   Annet: _____________ 
Hvis du bruker spiral eller prevensjonsmiddel på resept,
hvem går du vanligvis til for dette?
 Fastlegen   Gynekolog  Annen lege 
    
Helseundersøkelsen i Hordaland
Prosjekt om vanlige 
kvinneplager
Prosjektleder:
Professor Steinar Hunskår
Seksjon for allmennmedisin, Universitetet i Bergen
Kalfarveien 31, 5018  BERGEN
Tlf: 55 58 61 00  
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Dersom du ønsker det, kan du klippe vekk navnefeltet
HELSE, LIVSSTIL OG MOSJON OVERGANGSALDER OG PREVENSJON
Bla om!
 Hvor ofte har du vanligvis vannlating?
  _________  antall ganger i døgnet 
Må du vanligvis opp om natten på grunn av vannlating?
 Nei 1 gang 2 ganger 3 ganger Mer enn 3 ganger
      
Har du de siste 12 månedene hatt episoder med akutt svie, smerte 
eller ubehag ved vannlatingen?
 Nei 1-2 ganger 3-5 ganger Mer enn 5 ganger
     
 JA NEI
Var du plaget med sengevæting/nattevæting
som barn etter 5-6 års-alderen? ..................................  
Synes du at du som oftest får tømt 
blæren skikkelig ved vannlating? .................................   
Er du ofte plaget av 
sterk og brå vannlatingstrang? ....................................  
Opplever du urinlekkasje når du hoster, 
nyser, ler eller løfter tungt? ..........................................  
Opplever du urinlekkasje i forbindelse
med sterk og brå trang til vannlating? .........................  
Opplever du urinlekkasje i andre 
sammenhenger? ..........................................................  
Hvor ofte har du urinlekkasje? (Sett bare ett kryss)
 Aldri eller nesten aldri..................................................  
 Sjeldnere enn en gang i måneden ..............................  
 En eller flere ganger i måneden ..................................  
 En eller flere ganger i uken .........................................  
 Hver dag og/eller natt ..................................................  
Hvor mye urin lekker vanligvis hver gang? (Sett bare ett kryss)
 Har ikke  Dråper Små Større 
 lekkasje eller lite skvetter mengder
 
   
De neste spørsmålene gjelder barre hvis du har eller har hatt
lekkasjeplager:
Er du operert for urinlekkasje?.................................
Har du tidligere hatt urinlekkasje
og blitt bra uten behandling?...................................
Hvilket hjelpemiddel eller behandling bruker du eller
har du brukt for lekkasjeplager? Ikke Prøvd før Bruker nå
Medisiner ..................................    
Mensbind, truseinnlegg .............    
Spesialbleier .............................    
Knipøvinger ...............................    
Elektrostimulator .......................    
Hvordan opplever du lekkasjeplagene?
 Ikke noe problem .........................................................
 Lite plaget ....................................................................
 En del plaget ...............................................................
 Mye plaget ...................................................................  
 JA NEIHar du noen gang søkt
legehjelp for lekkasjeplagene? ...............................  
      
 JA NEI
Tok du noen medisin for helsen I GÅR? ...................  
Med medisin mener vi her alle typer, både:
• med og uten resept, naturmedisin, vitamin og mineral
• medisin som skal svelges, innhaleres eller injiseres, 
  stikkpiller, salver, kremer eller dropper.
Dersom JA:
Hvilken medisin tok du I GÅR? Hva var grunnen til at du tok 
medisinen (diagnose, sykdom, symptom, helseeffekt)?
Sett svarene inn i skjemaet nedenfor, en linje for hver medisin. 
Kryss av for ja hvis du bruker medisinen daglig eller nesten daglig.       
Dersom det ikke er plass nok her, kan du fortsette på et eget
ark som du legger ved skjemaet.
Dersom vi har brukt feil adresse, eller du vet at du skal endre
adresse, skriv den nye adressen i ruten. Du kan gi oss melding i 
et eget brev eller på telefon.
VANNLATING
Navn på medisinen
(ett navn pr. linje):
 Grunn til bruk av 
medisinen
I GÅR var:
Daglig
JA       NEI  
Send svarskjemaet i den frankerte konvolutten i dag.
Takk for hjelpen!
JA      NEI
BRUK AV MEDISIN, NATURLEGEMIDDEL m.m.
Errata 
 
Paper I  
Page 1500, Material and method, Paragraph 2, line 8:  
The correct sentence shall read:  The doctors’ assessment of indications and 
contraindications was analysed by testing the response category “great 
emphasis” against the response categories “less emphasis” and “no 
emphasis” added together. (not .. was analysed by adding together the 
response categories “great emphasis” and “less emphasis” and testing them 
against “no emphasis”.)  
 
Paper II  
Page 1662, Table 4:  Figures in Column heading, Univariate analysis shall read: 
Recommend therapy (n=90-93, not 89) vs advice against  + no advice 
given (n=193-196 not 186) 
Figures in Column heading, Multivariate analysis shall read: 
Recommend therapy (n=86 not 89) vs advice against + no advice 
given (n=189 not 186) 
 
Page 1662, Table 5: Figures in Column heading, Univariate analysis shall read: 
Recommend therapy (n=60-63, not 89) vs advice against  + no advice 
given (n=220-225 not 186) 
Figures in Column heading, Multivariate analysis shall read: 
Recommend therapy (n=60 not 89) vs advice against + no advice 
given (n=217 not 186) 
 

